US20050106648A1 - Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus - Google Patents

Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus Download PDF

Info

Publication number
US20050106648A1
US20050106648A1 US11/020,509 US2050904A US2005106648A1 US 20050106648 A1 US20050106648 A1 US 20050106648A1 US 2050904 A US2050904 A US 2050904A US 2005106648 A1 US2005106648 A1 US 2005106648A1
Authority
US
United States
Prior art keywords
antibody
protein
aureus
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/020,509
Inventor
Timothy Foster
Fiona Roche
Mark Pallen
Joseph Patti
Jeff Hutchins
Pietro Speziale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/020,509 priority Critical patent/US20050106648A1/en
Publication of US20050106648A1 publication Critical patent/US20050106648A1/en
Priority to US12/365,481 priority patent/US7968100B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates in general to surface proteins from Staphylococcus aureus and their active regions such as their A domains which have homologue proteins on coagulase-negative Staphylococci such as S. epidermidis and S. hemolyticus as well as antibodies which recognize said proteins, and in particular to isolated monoclonal and polyclonal antibodies which recognize specific proteins from Staphylococcus aureus and coagulase-negative Staphylococci and which are cross-reactive against S. aureus and coagulase-negative Staphylococci and can thus be utilized in vaccines and methods useful for preventing or treating a wide variety of infections caused by staphylococcal bacteria.
  • Microbial adhesion is the first crucial step in a series of events that can eventually lead to disease.
  • Pathogenic microorganisms colonize the host by attaching to host tissues or serum conditioned implanted biomaterials, such as catheters, artificial joints, and vascular grafts, through specific adhesins present on the surface of the bacteria.
  • MSCRAMM®s Microbial Surface Components Recognizing Adhesive Matrix Molecules
  • MSCRAMM®s are a family of cell surface adhesins that recognize and specifically bind to distinct components in the host's extracellular matrix.
  • adherent bacteria Once the bacteria have successfully adhered and colonized host tissues, their physiology is dramatically altered and damaging components such as toxins and proteolytic enzymes are secreted. Moreover, adherent bacteria often produce a biofilm and quickly become more resistant to the killing effect of most antibiotics.
  • S. aureus causes a spectrum of infections that range from cutaneous lesions such as wound infections, impetigo, and furuncles to life-threatening conditions that include pneumonia, septic arthritis, sepsis, endocarditis, and biomaterial related infections.
  • S. aureus is known to express a repertoire of different MSCRAMMs that can act individually or in concert to facilitate microbial adhesion to specific host tissue components.
  • another type of staphylococcus bacteria is identified as the coagulase-negative bacteria, including such species as S. epidermidis and S. hemolyticus which are also have been known to express MSCRAMMs, and which also are responsible for a wide range of bacterial infections and related diseases.
  • MSCRAMMs generally provide an excellent target for immunological attack by antibodies, both polyclonal and monoclonal antibodies.
  • MSCRAMM® is also an object of the present invention to identify and isolate MSCRAMM®'s from staphylococcal bacteria, as well as their active regions such as the A domain, which can be used to generate monoclonal and polyclonal antibodies that will be cross-reactive against both coagulase-positive and coagulase-negative staphylococci.
  • the present invention comprises the identification and isolation of surface proteins from one type of staphylococcal bacteria, such as coagulase-negative or coagulase-positive staph, which can give rise to cross-reactive antibodies which can recognize surface proteins of both types of staph and which can thus be utilized in vaccines and methods of treating or preventing a wide range of staphylococcal infections.
  • the present invention also relates to the generation of both polyclonal and monoclonal antibodies from these surface proteins and their use in preventing or treating staphylococcal infections.
  • FIG. 1 is a depiction of the primary structure of the in silico-predicted proteins in accordance with the present invention.
  • FIG. 2 shows a Coomassie gel of the purified N-terminal recombinant His-tagged proteins expressing the orfs of the present invention.
  • FIGS. 3A-3C show Western blotting of S. aureus cell wall extracts showing probing with anti-KesK antibodies ( FIG. 3A ), anti-KnkA antibodies ( FIG. 3B ) and anti-DsqA antibodies ( FIG. 3C ), respectively.
  • FIGS. 4A-4B show Dot-blotting and Western immunoblotting of Lactococcus lactis expressing S. aureus MSCRAMM®s, namely KnkA ( FIG. 4A ) and KesK ( FIG. 4B ).
  • FIGS. 5A-5D representing the probing of recombinant LPXTG proteins in accordance with the present invention with convalescent sera examining in vivo expression, including RrKn and RrKN2 ( FIG. 5A ), Kesk1 and Kesk2A ( FIG. 5B ), KnkA ( FIG. 5C ) and DsqA2 ( FIG. 5D ).
  • FIG. 6 shows a Western blot analysis demonstrating that rabbit polyclonal antibodies against S. aureus SasA cross-react with a protein released from the cell surface of S. epidermidis HB as well as the recombinant A-region from DsgK cloned from S. epidermidis.
  • specific surface proteins from coagulase-positive staphylococcal bacteria such as S. aureus
  • coagulase-negative staph such as S. epidermidis and S. hemolyticus
  • active fragments thereof such -as the A domains of these proteins or other epitotic regions which can generate antibodies that recognize the whole protein.
  • MSCRAMM®s (Microbial Surface Components Recognizing Adhesive Matrix Molecules) which are in most cases are covalently anchored to the cell wall peptidoglycan.
  • EkeS ENCSJM 2189 aa LPNTGSEEMDLPLKELALITGAALLRRRS KKEKES DsqA ENCSJM ⁇ 1363- LPDTGDSIKQNGLLGGVMTLLVGLGLMKR 2283 aa KKKKDENDQDDSQA KesK ENCSJM ⁇ 909 aa LPKTGETTSSQSWWGLYALLGMLALFIPK FRKESK KrkN2 ENCSJM ⁇ 278 aa LPKTGLTSVDNFISTVAFATLALLGSLSLLLF (Cowan) KRKESK KrkN ENCSJM ⁇ 661 aa LPQTGEESNKDMTLPLMALIALSSIVAFVLP RKRKN RkaS ENCSJM ⁇ 801 aa LPKTGTNQSSSPEAMFVLLAGIGLIATVRR RKAS RrkN NCSJM 1629 aa LPKTGLESTQKGLIFSS
  • isolated antibodies may be generated from the above proteins or their active regions such as the A domain so as to be able to recognize said proteins and/or said domains.
  • These antibodies may be either monoclonal or polyclonal. If polyclonal antibodies are desired, these may be generated in any of a number of conventional ways well known in the art.
  • the desired surface protein or active region thereof may be injected into a suitable host animal, e.g., a mouse or rabbit, and after a suitable time period, antibodies may be isolated and recovered from the host animal.
  • monoclonal antibodies in accordance with the present invention, these may be produced in any number of suitable ways including, e.g., the well known method of Kohler and Milstein, Nature 256:495-497 (1975), or other suitable ways known in the field, such as those methods disclosed in U.S. Pat. Nos. 6,331,415; 5,981,216; 5,807,715; and 4,816,567; Eur. Pat. App. 519,596; and PCT publication WO 00/71585, all of these patent publications incorporated herein by reference. These methods include their preparation as chimeric, humanized, or human monoclonal antibodies in ways that would be well known in this field.
  • monoclonal antibodies may be prepared from a single chain, such as the light or heavy chains, and in addition may be prepared from active fragments of an antibody which retain the binding characteristics (e.g., specificity and/or affinity) of the whole antibody.
  • active fragments is meant an antibody fragment which has the same binding specificity as a complete antibody which binds to the particular surface protein or its homologue from the different type of staph bacteria (i.e., coagulase negative or coagulase-positive), and the term “antibody” as used herein is meant to include said fragments.
  • antisera prepared using monoclonal or polyclonal antibodies in accordance with the invention are also contemplated and may be prepared in a number of suitable ways as would be recognized by one skilled in the art.
  • antibodies to the isolated surface proteins and/or their active regions in accordance with the invention may be prepared in a number of suitable ways that would be well known in the art, such as the well-established Kohler and Milstein method described above which can be utilized to generate monoclonal antibodies.
  • mice may be injected intraperitoneally once a week for a prolonged period with a purified recombinant MSCRAMM® in accordance with the invention or an active portion thereof, followed by a test of blood obtained from the immunized mice to determine reactivity to the purified protein.
  • lymphocytes isolated from mouse spleens are fused to mouse myeloma cells to produce hybridomas positive for the antibodies against the surface proteins of the invention which are then isolated and cultured, following by purification and isotyping.
  • these be generated using recombinantly prepared MSCRAMM®'s in accordance with the invention, and these recombinants may be generated and isolated using a number of standard methods well known in the art.
  • one such method employs the use of E. coli expression vector pQE-30 as an expression vector for cloning and expressing recombinant proteins and peptides.
  • E. coli expression vector pQE-30 as an expression vector for cloning and expressing recombinant proteins and peptides.
  • the A domain of the surface protein identified as DgsK or SasA was amplified from the sequences described above and subcloned into the E.
  • coli expression vector PQE-30 (Qiagen), which allows for the expression of a recombinant fusion protein containing six histidine residues.
  • This vector was subsequently transformed into E. coli strain ATCC 55151, grown in a 15-liter fermentor to an optical density (OD 600 ) of 0.7 and induced with 0.2 mM isopropyl-1-beta-D galactoside (IPTG) for 4 hours.
  • the cells were harvested using an AG Technologies hollow-fiber assembly (pore size 0.45 ⁇ m) and the cell paste frozen at ⁇ 80° C. Cells were lysed in 1 ⁇ PBS (10 mL buffer/1 g of cell paste) using 2 passes through the French Press @ 1100 psi.
  • Lysed cells were spun down at 17,000 rpm for 30 minutes to remove cell debris. Supernatant was passed over a 5-mL HiTrap Chelating (Pharmacia) column charged with 0.1M NiCl 2 . After loading, the column was washed with 5 column volumes of 10 mM Tris, pH 8.0, 100 mM NaCl (Buffer A). Protein was eluted using a 0-100% gradient of 10 mM Tris, pH 8.0, 100 mM NaCl, 200 mM imidazole (Buffer B) over 30 column volumes. SdrGNlN2N3 or SdrGN2N3 eluted at ⁇ 13% Buffer B ( ⁇ 26mM imidazole). Absorbance at 280nm was monitored. Fractions containing SdrGN1N2N3 or SdrGN2N3 were dialyzed in 1 ⁇ PBS.
  • each protein was then put through an endotoxin removal protocol. Buffers used during this protocol were made endotoxin free by passing over a 5-mL Mono-Q sepharose (Pharmacia) column. Protein was divided evenly between 4 ⁇ 15 mL tubes. The volume of each tube was brought to 9 mL with Buffer A. 1 mL of 10% Triton X-114 was added to each tube and incubated with rotation for 1 hour at 4° C. Tubes were placed in a 37° C. water bath to separate phases. Tubes were spun down at 2,000 rpm for 10 minutes and the upper aqueous phase from each tube was collected and the detergent extraction repeated.
  • Aqueous phases from the 2nd extraction were combined and passed over a 5-mL IDA chelating (Sigma) column, charged with 0.1M NiCl 2 to remove remaining detergent.
  • the column was washed with 9 column volumes of Buffer A before the protein was eluted with 3 column volumes of Buffer B.
  • the eluant was passed over a 5-mL Detoxigel (Sigma) column and the flow-through collected and reapplied to the column.
  • the flow-through from the second pass was collected and dialyzed in 1 ⁇ PBS.
  • the purified product was analyzed for concentration, purity and endotoxin level before administration into the mice.
  • monoclonal antibodies in accordance with the present invention may be prepared from the recombinant proteins identified above in the following manner.
  • E. coli expressed and purified recombinant SasA and DsgK proteins were used to generate a panel of murine monoclonal antibodies while the mouse sera was used as a source of polyclonal antibodies.
  • a group of Balb/C or SJL mice received a series of subcutaneous immunizations of 1-10 mg of protein in solution or mixed with adjuvant as described below in Table 2.
  • bacterial cells were incubated with Goat-F (ab′)2 -Anti-Mouse-F (ab′)2 -FITC which served as the detection antibody. After antibody labeling, bacterial cells were aspirated through the FACScaliber flow cytometer to analyze fluorescence emissipon (excitation: 488, emission: 570). For each bacterial strain, 10,000 events were collected and measured. These data indicate that antibodies against S. aureus SasA were able to recognize a homologous protein on the surface of coagulase-negative staphylococci. The data support Western blot analysis demonstrating that rabbit polyclonal antibodies against S. aureus SasA cross-react with a protein released from the cell surface of S.
  • antibodies may be generated from natural isolated and purified versions of these proteins or their active regions such as the A domain, and monoclonal or polyclonal antibodies can be generated using these proteins or active regions in the same manner as described above to obtain such antibodies. Still other conventional ways are available to generate the antibodies of the present invention using recombinant or natural purified proteins or their active regions, as would be recognized by one skilled in the art.
  • the antibodies of the present invention may also be formed into suitable pharmaceutical compositions for administration to a human or animal patient in order to treat or prevent an infection caused by staphylococcal bacteria.
  • Pharmaceutical compositions containing the antibodies of the present invention, or effective fragments thereof may be formulated in combination with any suitable pharmaceutical vehicle, excipient or carrier that would commonly be used in this art, including such as saline, dextrose, water, glycerol, ethanol, other therapeutic compounds, and combinations thereof.
  • suitable pharmaceutical vehicle, excipient or carrier will vary depending on the patient and the patient's condition, and a variety of modes of administration would be suitable for the compositions of the invention, as would be recognized by one of ordinary skill in this art.
  • Suitable methods of administering any pharmaceutical composition disclosed in this application include, but are not limited to, topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal and intradermal administration.
  • the composition is formulated in the form of an ointment, cream, gel, lotion, drops (such as eye drops and ear drops), or solution (such as mouthwash). Wound or surgical dressings, sutures and aerosols may be impregnated with the composition.
  • the composition may contain conventional additives, such as preservatives, solvents to promote penetration, and emollients. Topical formulations may also contain conventional carriers such as cream or ointment bases, ethanol, or oleyl alcohol.
  • suitable adjuvants may include alum (aluminum phosphate or aluminum hydroxide), which is used widely in humans, and other adjuvants such as saponin and its purified component Quil A, Freund's complete adjuvant, RIBBI adjuvant, and other adjuvants used in research and veterinary applications. Still other chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. J. Immunol.
  • encapsulation of the conjugate within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992) and incorporated by reference herein, and encapsulation of the protein in lipid vesicles such as NovasomeTM lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.) may also be useful.
  • lipid vesicles such as NovasomeTM lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.) may also be useful.
  • the antibody compositions of the present invention which recognize the proteins or their active regions as set forth above will be useful in methods of preventing or treating staphylococcal infection, and in inhibiting binding of staphylococcal bacteria to host tissue and/or cells.
  • methods for preventing or treating a staphylococcal infection which comprise administering an effective amount of an antibody to the surface proteins as set forth herein or their active subregions so as to treat or prevent a staphylococcal infection.
  • these monoclonal antibodies will be useful in impairing the binding of staphylococcal bacteria to host cells
  • administering in any of the conventional ways described above (e.g., topical, parenteral, intramuscular, etc.), and will thus provide an extremely useful method of treating or preventing staphylococcal infections in human or animal patients when an effective amount of the antibody compositions are administered to a human or animal patient.
  • effective amount is meant that level of use, such as of an antibody titer, that will be sufficient to either prevent adherence of the bacteria, to inhibit binding of staph bacteria to host cells and thus be useful in the treatment or prevention of a staph infection.
  • the level of antibody titer needed to be effective in treating or preventing staphylococcal infection will vary depending on the nature and condition of the patient, and/or the severity of the pre-existing staphylococcal infection.
  • the antibodies of the invention may also be used for the specific detection of staphylococcal proteins, or as research tools.
  • the term “antibodies” as used herein includes monoclonal, polyclonal, chimeric, single chain, bispecific, simianized, and humanized or primatized antibodies as well as Fab fragments, such as those fragments which maintain the binding specificity of the antibodies to the surface proteins specified above, including the products of an Fab immunoglobulin expression library. Accordingly, the invention contemplates the use of single chains such as the variable heavy and light chains of the antibodies. Generation of any of these types of antibodies or antibody fragments is well known to those skilled in the art. In the present case, antibodies to the surface proteins or their active regions as referred to above can be generated, isolated and/or purified, and then used to treat or protect against staphylococcal infection.
  • any of the above described antibodies may be labeled directly with a detectable label for identification and quantification of staph bacteria.
  • Labels for use in immunoassays are generally known to those skilled in the art and include enzymes, radioisotopes, and fluorescent, luminescent and chromogenic substances, including colored particles such as colloidal gold or latex beads.
  • Suitable immunoassays include enzyme-linked immunosorbent assays (ELISA).
  • the antibody may be labeled indirectly by reaction with labeled substances that have an affinity for immunoglobulin.
  • the antibody may be conjugated with a second substance and detected with a labeled third substance having an affinity for the second substance conjugated to the antibody.
  • the antibody may be conjugated to biotin and the antibody-biotin conjugate detected using labeled avidin or streptavidin.
  • the antibody may be conjugated to a hapten and the antibody-hapten conjugate detected using labeled anti-hapten antibody.
  • vaccines for either active or passive immunization designed to treat or protect against staphylococcal infections
  • these vaccines may be prepared from the surface proteins or their active regions as set forth above using a number of the conventional vaccine preparation methods well known in this field.
  • an immunogenic amount of a suitable surface protein or active fragment thereof is combined with a suitable pharmaceutically acceptable vehicle, carrier or excipient, and an amount of this vaccine effective to immunize a human or animal patient may be administered as appropriate.
  • immunogenic amount it would be understood by one of ordinary skill in this art that this refers to any amount of the protein or active fragment or subregion thereof which is able to raise an immunogenic response in the human or animal patient.
  • the isolated antibodies of the present invention, or active fragments thereof may also be utilized in the development of vaccines for passive immunization against staph infections.
  • the antibody compositions as described above namely an effective amount of the antibody and a pharmaceutically acceptable vehicle, carrier or excipient, may be administered as appropriate to a human or animal patient.
  • the proteins or active fragments thereof may be utilized as active vaccines, and the antibodies of the invention may be used as a passive vaccine which will be useful in providing suitable antibodies to treat or prevent a staphylococcal infection.
  • a vaccine may be packaged for administration in a number of suitable ways, such as by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration.
  • the vaccine is injected intramuscularly, e.g., into the deltoid muscle, however, the particular mode of administration will depend on the nature of the bacterial infection to be dealt with and the condition of the patient.
  • the vaccine is preferably combined with a pharmaceutically acceptable vehicle, carrier or excipient to facilitate administration, and the carrier is usually water or a buffered saline, with or without a preservative.
  • the vaccine may be lyophilized for resuspension at the time of administration or in solution.
  • the antibodies of the present invention may be modified as necessary so that, when necessary, they become less immunogenic in the patient to whom it is administered.
  • the antibody may be “humanized” by transplanting the complimentarity determining regions of the hybridoma-derived antibody into a human monoclonal antibody as described, e.g., by Jones et al., Nature 321:522-525 (1986) or Tempest et al. Biotechnology 9:266-273 (1991) or “veneered” by changing the surface exposed murine framework residues in the immunoglobulin variable regions to mimic a homologous human framework counterpart as described, e.g., by Padlan, Molecular Imm. 28:489-498 (1991), these references incorporated herein by reference.
  • the monoclonal antibodies of the present invention may be administered in conjunction with a suitable antibiotic to further enhance the ability of the present compositions to fight bacterial infections when necessary.
  • compositions may also be used to halt or prevent infection of a medical device or other biomaterials such as an implant.
  • Medical devices or polymeric biomaterials to be coated with the antibodies, proteins and active fragments described herein include, but are not limited to, staples, sutures, replacement heart valves, cardiac assist devices, hard and soft contact lenses, intraocular lens implants (anterior chamber or posterior chamber), other implants such as corneal inlays, kerato-prostheses, vascular stents, epikeratophalia devices, glaucoma shunts, retinal staples, scleral buckles, dental prostheses, thyroplastic devices, laryngoplastic devices, vascular grafts, soft and hard tissue prostheses including, but not limited to, pumps, electrical devices including stimulators and recorders, auditory prostheses, pacemakers, artificial larynx, dental implants, mammary implants, penile implants, cranio/facial tendons, artificial joints, tendons, ligament
  • coated means to apply the antibody or active fragment, or pharmaceutical composition derived therefrom, to a surface of the device, preferably an outer surface that would be exposed to streptococcal bacterial infection.
  • the surface of the device need not be entirely covered by the protein, antibody or active fragment.
  • an “effective amount” of antibody or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the agent, such that the desired prophylactic or therapeutic effect is produced.
  • the exact amount of the antibody or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like.
  • the “effective amount” of any particular antibody composition will vary based on the particular circumstances, and an appropriate effective amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation.
  • the dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual.
  • the compositions may also contain stabilizers or pharmaceutically acceptable preservatives, such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, Mo.).
  • the monoclonal antibodies described herein are useful for purposes such as in vivo and in vitro diagnosis of staphylococcal infections or detection of staphylococcal bacteria. Laboratory research may also be facilitated through use of such antibodies.
  • Various types of labels and methods of conjugating the labels to the antibodies of the invention are well known to those skilled in the art, such as the ones set forth below.
  • the antibody can be conjugated (directly or via chelation) to a radiolabel such as, but not restricted to, 32 P, 3 H, 14 C, 35 S, 125I, or 131 I.
  • a radiolabel such as, but not restricted to, 32 P, 3 H, 14 C, 35 S, 125I, or 131 I.
  • Detection of a label can be by methods such as scintillation counting, gamma ray spectrometry or autoradiography.
  • Bioluminescent labels such as derivatives of firefly luciferin, are also useful.
  • the bioluminescent substance is covalently bound to the protein by conventional methods, and the labeled protein is detected when an enzyme, such as luciferase, catalyzes a reaction with ATP causing the bioluminescent molecule to emit photons of light. Fluorogens may also be used to label proteins.
  • fluorogens examples include fluorescein and derivatives, phycoerythrin, allo-phycocyanin, phycocyanin, rhodamine, and Texas Red.
  • the fluorogens are generally detected by a fluorescence detector.
  • the location of a ligand in cells can be determined by labeling an antibody as described above and detecting the label in accordance with methods well known to one skilled in the art, such as immunofluorescence microscopy using procedures such as those described by Warren et al. ( Mol. Cell. Biol., 7: 1326-1337, 1987).
  • the monoclonal antibodies of the present invention are particularly useful for interfering with the initial physical interaction between a staphylococcal pathogen responsible for infection and a mammalian host, and this interference with the physical interaction may be useful both in treating patients and in preventing or reducing bacteria infection on in-dwelling medical devices to make them safer for use.
  • a kit will typically include a suitable container for housing the antibodies in a suitable form along with a suitable immunodetection reagent which will allow identification of complexes binding to the surface proteins or the antibodies of the invention.
  • these kits may contain an antibody in accordance with the invention and means to identify binding of that antibody when a sample from a patient is introduced to the antibody.
  • a suitable immunodetection reagent may comprise an appropriate detectable signal or label, such as a biotin or enzyme that produces a detectable color, etc., which may be linked to the antibody or utilized in other suitable ways so as to provide a detectable result when the antibody binds to the antigen.
  • an appropriate detectable signal or label such as a biotin or enzyme that produces a detectable color, etc.
  • the antibodies of the preset invention which recognize and bind to the surface proteins of the invention, or active fragments thereof, will thus be useful in treating a wide variety of staphylococcal infections in human and animal patients and in medical or other in-dwelling devices.
  • the antibodies of the invention because of the nature of these proteins and the fact that they contain epitopes in common with proteins of the other type of staphylococcal bacteria, i.e., a protein from a coagulase-negative staph will raise antibodies that recognize a homologous protein from S. aureus and vice versa, the antibodies of the invention will exhibit cross-reactivity and should be effective against a broad range of staphylococcal infections. Accordingly, the present invention provides methods and compositions for improved methods of treating or protecting against a wide range of staphylococcal infections.
  • Staphylococcus aureus is known to express a class of surface-associated proteins which play important roles in pathogenicity by allowing bacteria to avoid host defenses and by acting as adhesins. These proteins are known as MSCRAMMs (Microbial Surface Components Recognizing Adhesive Matrix Molecules) and in most cases are covalently anchored to the cell wall peptidoglycan.
  • MSCRAMMs Microbial Surface Components Recognizing Adhesive Matrix Molecules
  • an N-terminal signal peptide (approximately 40 residues in length) required for Sec-dependent secretion, (ii) a wall spanning domain either rich in proline and glycine residues or composed of serine and aspartate dipeptide repeats, (iii) an LPXTG motif required for covalent anchoring of the protein to the pentaglycine crossbridge in peptidoglycan, (iv) a hydrophobic membrane-spanning domain followed by (v) several positively charged residues.
  • EkeS ENCSJM 2189 aa LPNTGSEEMDLPLKELALITGAALLARRRS KKEKES DsqA ENCSJM ⁇ 1363- LPDTGDSIKQNGLLGGVMTLLVGLGLMKR 2283 aa KKKKDENDQDDSQA KesK ENCSJM ⁇ 909 aa LPKTGETTSSQSWWGLYALLGMLALFIPK FRKESK KrkN2 ENCSJM ⁇ 278 aa LPKTGLTSVDNFISTVAFATLALLGSLSLLLF (Cowan) KRKESK KrkN ENCSJM ⁇ 661 aa LPQTGEESNKDMTLPLMALIALSSIVAFVLP RKRKN RkaS ENCSJM ⁇ 801 aa LPKTGTNQSSSPEAMFVLLAGIGLIATVRR RKAS RrkN NCSJM 1629 aa LPKTGLESTQKGLIFSSII
  • RrkN and DsqA possessed a similar structural organization to previously described MSCRAMMs.
  • RrkN is similar in structure to the Pls/Aap proteins of S. aureus and S. epidermidis, respectively. It contains a 200-residue domain at its N-terminus showing 40% identity to Pls and Aap.
  • the C-terminus of the protein is predominantly composed of a 128 residue repeat domain, which varies in the numbers of repeats from strain to strain. These repeats are also present in Pls and Aap.
  • a putative sar homolog and fnbpA and fnbpB lie directly upstream from RrkN on the genome.
  • DsqA is similar in structural organization to the Sdr family of proteins. It contains a typical A domain followed by a TYYFTDVK motif which is similar to a conserved TYTFTVYVD motif found in all of the Sdr proteins. The function of this motif has yet to be determined. Two 88 residue repeat domains reside in the centre of the protein followed by a C-terminal SX-repeat motif similar to the SD-repeat motif found in the Sdr proteins. The size of this repeat varies from strain to strain. DsqA neighbors secY and secA on the genome. A DsqA homolog (>90% identical) is also found in S. epidermidis.
  • KnkA contains no repeat domains in its sequence. Secondary structure prediction analysis indicate that this protein is predominantly composed of alpha-helices.
  • RkaS contains no repeat domains in its sequence. BLAST analysis indicates that it is similar to a 5′ nucleotidase UDP-sugar hydrolase. The gene encoding RkaS lies directly upstream from orfX, the insertion site of the mec element.
  • KesK contains two 140 residue repeat domains at the N-terminus of the protein which are 38% identical. Hydropathy plot analysis (Kyte and Doolittle, 1982) indicates that there is a large hydrophilic domain in the center of the protein (residue 500-560).
  • EkeS contains two 300 residue repeat domains in the center of the protein which are 38% identical. Blast analysis indicates that the N-terminus of the protein (residues 1-1268, bearing both repeats) is 49% identical to FmtB, an LPXTG protein with 17 tandem repeats. FmtB is proposed to be involved indirectly in methicillin resistance as inactivation of fmtB abolishes methicillin resistance. This appears to be due to affecting cell wall composition as methicillin sensitivity can be relieved by increasing the production of the cell wall precursor glucosamine-1-phosphate (Komatsuzawa et al., 2000).
  • KrkN and KrkN2 neighbor each other on the genome.
  • FIG. 2 represents a Coomassie stained SDS-PAGE gel of the purified N-terminal his-tag fusion proteins.
  • the recombinant proteins RrkN1, DsqA2, KesK1 and KnkA were used to generate antibodies in rabbits.
  • Western blotting analysis of S. aureus cell wall extracts revealed that KesK, KnkA and DsqA are expressed and cell wall-associated ( FIG. 3 ).
  • Strain eMRSA-16 represents a knkA-negative strain since it lacks the knkA gene.
  • An immunoreactive band of 65 kDa reacts with the cell wall fraction from both exponential and stationary phase cells of strain 8325-4 ( FIG. 3 , B). The absence of this band in strain eMRSA-16 suggests that it represents the gene product of knkA.
  • aureus contains two sortase genes, srtA and srtB (Pallen, 2001). It is possible that this variant form of the LPXTG motif is processed by the second sortase gene, which is absent in L. lactis. This would also explain the slight increase in size of the KnkA protein observed in the protoplast fraction, as the cell wall sorting signal has not been cleaved.
  • KesK was detected in the cell wall fraction of L. lactis but migrated at a smaller molecular weight than the KesK protein released from the cell wall of S. aureus.
  • the majority of MSCRAMMs expressed on the surface of L. lactis are prone to proteolysis during the cell wall extraction procedure (Louise O'Brien, personal communication). Therefore, it is possible that the KesK protein released from the surface of L. lactis represents a truncated form of KesK. Shorter digestion times with lysozyme and mutanolysin has been shown to limit the extent of proteolysis.
  • FIGS. 5A-5D illustrate that all of the proteins were recognized by 27-42% of the patients suggesting that these proteins are expressed in vivo and are immunogenic during infection of the host.
  • S. epidermidis contains surface proteins structurally related to S. aureus MSCRAMM® proteins (U.S. Ser. No. 09/386,962).
  • One protein from S. aureus is of particular interest since it has a close homologue in S. epidermidis.
  • the protein is called DsqA or SasA ( S. aureus ) and DgsK ( S. epidermidis ). They are characterized by a typical “A” domain of approximately 500 amino acid residues, followed by two B repeats of 88 residues that are ⁇ 40% identical, and a unique SXSX dipeptide repeat that can vary in length depending on the strain. Contained within the A domain of the S.
  • aureus DsqA/SasA is a 180 residue region that has ⁇ 40% identity to a similar sized domain within region A of S. aureus proteins RrkN, Pls and S. epidermidis protein Aap
  • the A regions of the DsqA/SasA and DgsK proteins are 46% identical at the amino acid level, the BB repeats are 50% identical.
  • Active and passive immunization strategies that include; vaccines, polyclonal and monoclonal antibodies recognizing both S. aureus and coagulase-negative staphylococcal proteins are the subject of this invention.
  • Coagulase-negative staphylococcal DgsK A-Domain Amino Acid Sequence ASETPITSEISSNSETVANQNSTTIKNSQKETVNSTSLESNHSNSTNKQMSSEVTN (SEQ ID NO:17) TAQSSEKAGISQQSSETSNQSSKLNTYASTDHVESTTINNDNTAQQDQNKSSNVT SKSTQSNTSSSEKNISSNLTQSIETKATDSLATSEARTSTNQISNLTSTSTSNQSSP TSFANLRTFSRFTVLNTMAAPTTTSTTTTSSLTSNSVVVNKDNFNEHMNLSGSATY DPKTGIATLTPDAYSQKGAISLNTRLDSNRSFRFIGKVNLGNRYEGYSPDGVAGGD GIGFAFSPGPLGQIGKEGAAVGIGGLNNAFGFKLDTYHNTSTPRSDAKAKADPRN VGGGGAFGAFVSTDRNGMATTEESTAAKLNVQPTDNSFQDFVIDYNGDTKVM
  • aureus SasA A-domain: Amino Acid Sequence ASDAPLTSELNTQSETVGNQNSTTIEASTSTADSTSVTKNSSSVQTSNSDTVSSEK (SEQ ID NO:18) SEKVTSTTNSTSNQQEKLTSTSESTSSKNTTSSSDTKSVASTSSTEQPINTSTNQS TASNNTSQSTTPSSVNLNKTSTTSTSTAPVKLRTFSRLAMSTFASAATTTAVANTI TVNKDNLKQYMTTSGNATYDQSTGIVTLTQDAYSQKGAITLGTRIDSNKSFHFSGK VNLGNKYEGHGNGGDGIGFAFSPGVLGETGLNGAAVGIGGLSNAFGFKLDTYHNT SKPNSAAKANADPSNVAGGGAFGAFVTTDSYGVATTYTSSSTADNAAKLNVQPT NNTFQDFDINYNGDTKVMTVKYAGQTWTRNISDWIAKSGTTNFSLSMTASTGGAT NLQQVQFGTFEYTESAVT
  • the A domain of DgsK or SasA was amplified from the sequences described above and subcloned into the E. coli expression vector PQE-30 (Qiagen), which allows for the expression of a recombinant fusion protein containing six histidine residues.
  • This vector was subsequently transformed into the E. coli strain ATCC 55151, grown in a 15-liter fermentor to an optical density (OD 600 ) of 0.7 and induced with 0.2 mM isopropyl-1-beta-D galactoside (IPTG) for 4 hours.
  • the cells were harvested using an AG Technologies hollow-fiber assembly (pore size of 0.45 Om) and the cell paste frozen at ⁇ 80° C.
  • SdrGN1N2N3 or SdrGN2N3 eluted at ⁇ 13% Buffer B (26 mM imidazole). Absorbance at 280 nm was monitored. Fractions containing SdrGN1N2N3 or SdrGN2N3 were dialyzed in 1 ⁇ PBS.
  • Each protein was then put through an endotoxin removal protocol. Buffers used during this protocol were made endotoxin free by passing over a 5-mL Mono-Q sepharose (Pharmacia) column. Protein was divided evenly between 4 ⁇ 15 mL tubes. The volume of each tube was brought to 9 mL with Buffer A. 1 mL of 10% Triton X-114 was added to each tube and incubated with rotation for 1 hour at 4° C. Tubes were placed in a 37° C. water bath to separate phases. Tubes were spun down at 2,000 rpm for 10 minutes and the upper aqueous phase from each tube was collected and the detergent extraction repeated.
  • Aqueous phases from the 2nd extraction were combined and passed over a 5-mL IDA chelating (Sigma) column, charged with 0.1M NiCl 2 to remove remaining detergent.
  • the column was washed with 9 column volumes of Buffer A before the protein was eluted with 3 column volumes of Buffer B.
  • the eluant was passed over a 5-mL Detoxigel (Sigma) column and the flow-through collected and reapplied to the column.
  • the flow-through from the second pass was collected and dialyzed in 1 ⁇ PBS.
  • the purified product was analyzed for concentration, purity and endotoxin level before administration into the mice.
  • E. coli expressed and purified recombinant SasA and DsgK proteins were used to generate a panel of murine monoclonal antibodies while the mouse sera was used as a source of polyclonal antibodies.
  • a group of Balb/C or SJL mice received a series of subcutaneous immunizations of 1-10 mg of protein in solution or mixed with adjuvant as described in the Table below.
  • Any clones that were generated from the fusion were then screened for specific anti-SasA antibody production using a standard ELISA assay. Positive clones were expanded and tested further for activity in a whole bacterial cell binding assay by flow cytometry and SasA binding by Biacore analysis.
  • bacterial cells were incubated with Goat-F (ab′)2 -Anti-Mouse-F (ab′)2 -FITC which served as the detection antibody. After antibody labeling, bacterial cells were aspirated through the FACScaliber flow cytometer to analyze fluorescence emission (excitation: 488, emission: 570). For each bacterial strain, 10,000 events were collected and measured. These data indicate that antibodies against S. aureus SasA were able to recognize a homologous protein on the surface of coagulase-negative staphylococci. The data support Western blot analysis demonstrating that rabbit polyclonal antibodies against S. aureus SasA cross-react with a protein released from the cell surface of S.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus, are provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of staphylococcal infections.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application claims the benefit of U.S. provisional application Ser. No. 60/298,098 filed Jun. 15, 2001.
    • FIELD OF THE INVENTION
  • The present invention relates in general to surface proteins from Staphylococcus aureus and their active regions such as their A domains which have homologue proteins on coagulase-negative Staphylococci such as S. epidermidis and S. hemolyticus as well as antibodies which recognize said proteins, and in particular to isolated monoclonal and polyclonal antibodies which recognize specific proteins from Staphylococcus aureus and coagulase-negative Staphylococci and which are cross-reactive against S. aureus and coagulase-negative Staphylococci and can thus be utilized in vaccines and methods useful for preventing or treating a wide variety of infections caused by staphylococcal bacteria.
    • BACKGROUND OF THE INVENTION
  • The successful colonization of the host is a process required for most microorganisms to cause infections in animals and humans. Microbial adhesion is the first crucial step in a series of events that can eventually lead to disease. Pathogenic microorganisms colonize the host by attaching to host tissues or serum conditioned implanted biomaterials, such as catheters, artificial joints, and vascular grafts, through specific adhesins present on the surface of the bacteria. MSCRAMM®s (Microbial Surface Components Recognizing Adhesive Matrix Molecules) are a family of cell surface adhesins that recognize and specifically bind to distinct components in the host's extracellular matrix. Once the bacteria have successfully adhered and colonized host tissues, their physiology is dramatically altered and damaging components such as toxins and proteolytic enzymes are secreted. Moreover, adherent bacteria often produce a biofilm and quickly become more resistant to the killing effect of most antibiotics.
  • S. aureus causes a spectrum of infections that range from cutaneous lesions such as wound infections, impetigo, and furuncles to life-threatening conditions that include pneumonia, septic arthritis, sepsis, endocarditis, and biomaterial related infections. S. aureus is known to express a repertoire of different MSCRAMMs that can act individually or in concert to facilitate microbial adhesion to specific host tissue components. In addition, another type of staphylococcus bacteria is identified as the coagulase-negative bacteria, including such species as S. epidermidis and S. hemolyticus which are also have been known to express MSCRAMMs, and which also are responsible for a wide range of bacterial infections and related diseases. In this regard, MSCRAMMs generally provide an excellent target for immunological attack by antibodies, both polyclonal and monoclonal antibodies.
  • However, because antibodies by nature are very specific and in the case of different types of Staphylococci, such as S. aureus on one hand (coagulase-positive) and S. epidermidis and S. hemolyticus on the other (coagulase-negative), it has still remained a significant problem to develop antibodies that exhibit cross-reactivity across the different types of bacteria. Such cross-reactive antibodies are particularly desirable because of their potential in immunizing human and animal patients and providing protection against infections caused by both types of Staphylococcal bacteria, namely coagulase-positive bacteria such as S. aureus and the coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus. Such antibodies would thus be extremely useful in preventing or treating a wide variety of the infections caused by staphylococcal bacteria.
    • SUMMARY OF THE INVENTION
  • Accordingly, it is an object of the present invention to provide monoclonal antibodies that recognize MSCRAMM®'s from both coagulase-positive bacteria such as S. aureus as well as MSCRAMM®'s from coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus.
  • It is also an object of the present invention to identify and isolate MSCRAMM®'s from staphylococcal bacteria, as well as their active regions such as the A domain, which can be used to generate monoclonal and polyclonal antibodies that will be cross-reactive against both coagulase-positive and coagulase-negative staphylococci.
  • It is still further an object of the present invention to provide isolated antibodies that can recognize the A domain of surface proteins such as the DgsK protein from coagulase-negative staphylococci and at the same time recognize surface proteins such as the SasA protein from Staphylococcus aureus.
  • It is yet another object of the present invention to utilize the isolated proteins, A domains and antibodies of the invention to produce vaccines useful in the treatment or prevention of staphylococcal infections, and to provide methods wherein the vaccines and antibodies of the invention are used to prevent or treat a staphylococcal infection.
  • These and other objects are provided by virtue of the present invention which comprises the identification and isolation of surface proteins from one type of staphylococcal bacteria, such as coagulase-negative or coagulase-positive staph, which can give rise to cross-reactive antibodies which can recognize surface proteins of both types of staph and which can thus be utilized in vaccines and methods of treating or preventing a wide range of staphylococcal infections. The present invention also relates to the generation of both polyclonal and monoclonal antibodies from these surface proteins and their use in preventing or treating staphylococcal infections.
  • These embodiments and other alternatives and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the present specification and/or the references cited herein, all of which are incorporated by reference.
    • BRIEF DESCRIPTION OF THE DRAWING FIGURES
  • FIG. 1 is a depiction of the primary structure of the in silico-predicted proteins in accordance with the present invention.
  • FIG. 2 shows a Coomassie gel of the purified N-terminal recombinant His-tagged proteins expressing the orfs of the present invention.
  • FIGS. 3A-3C show Western blotting of S. aureus cell wall extracts showing probing with anti-KesK antibodies (FIG. 3A), anti-KnkA antibodies (FIG. 3B) and anti-DsqA antibodies (FIG. 3C), respectively.
  • FIGS. 4A-4B show Dot-blotting and Western immunoblotting of Lactococcus lactis expressing S. aureus MSCRAMM®s, namely KnkA (FIG. 4A) and KesK (FIG. 4B).
  • FIGS. 5A-5D representing the probing of recombinant LPXTG proteins in accordance with the present invention with convalescent sera examining in vivo expression, including RrKn and RrKN2 (FIG. 5A), Kesk1 and Kesk2A (FIG. 5B), KnkA (FIG. 5C) and DsqA2 (FIG. 5D).
  • FIG. 6 shows a Western blot analysis demonstrating that rabbit polyclonal antibodies against S. aureus SasA cross-react with a protein released from the cell surface of S. epidermidis HB as well as the recombinant A-region from DsgK cloned from S. epidermidis.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • In accordance with the present invention, there are provided specific surface proteins from coagulase-positive staphylococcal bacteria, such as S. aureus as well as from coagulase-negative staph such as S. epidermidis and S. hemolyticus, including active fragments thereof such -as the A domains of these proteins or other epitotic regions which can generate antibodies that recognize the whole protein. In accordance with the invention, the identification and isolation of candidate peptide sequences and proteins was carried out based on some of the common features of the MSCRAMM®s ((Microbial Surface Components Recognizing Adhesive Matrix Molecules) which are in most cases are covalently anchored to the cell wall peptidoglycan. These surface proteins had the following common features which were utilized in identifying and isolated the sequences of the present invention, namely: (i) an N-terminal signal peptide (approximately 40 residues in length) required for Sec-dependent secretion, (ii) a wall spanning domain either rich in proline and glycine residues or composed of serine and aspartate dipeptide repeats, (iii) an LPXTG motif required for covalent anchoring of the protein to the pentaglycine crossbridge in peptidoglycan, (iv) a hydrophobic membrane-spanning domain followed by (v) several positively charged residues.
  • In accordance with the invention, by exploiting the whole genome of S. aureus in light of the properties as set forth above, at least eight novel open reading frames encoding proteins with secretion and anchorage motifs indicative of MSCRAMMs were identified (i.e. bearing an N-terminal signal peptide and a C-terminal LPXTG motif followed by a hydrophobic domain and a positively charged tail). Table 1 illustrates the list of proteins identified including their distribution among S. aureus genomes, their protein size and C-terminal cell wall sorting sequence.
    TABLE 1
    Name Distribution Size C-terminus
    EkeS ENCSJM  2189 aa LPNTGSEEMDLPLKELALITGAALLRRRS
    KKEKES
    DsqA ENCSJM ˜1363- LPDTGDSIKQNGLLGGVMTLLVGLGLMKR
     2283 aa KKKKDENDQDDSQA
    KesK ENCSJM  ˜909 aa LPKTGETTSSQSWWGLYALLGMLALFIPK
    FRKESK
    KrkN2 ENCSJM  ˜278 aa LPKTGLTSVDNFISTVAFATLALLGSLSLLLF
    (Cowan) KRKESK
    KrkN ENCSJM  ˜661 aa LPQTGEESNKDMTLPLMALIALSSIVAFVLP
    RKRKN
    RkaS ENCSJM  ˜801 aa LPKTGTNQSSSPEAMFVLLAGIGLIATVRR
    RKAS
    RrkN NCSJM  1629 aa LPKTGLESTQKGLIFSSIIGIAGLMLLARRRK
    N
    KnkA NCSJM  629 aa LPKAGETIKEHWLPISVIVGAMGVLMIWLS
    RRNKLKNKA

    Abbreviations: eMRSA-16; N, 8325; C, COL; S, MSSA; J, N315, M, Mu50. Six out of eight are conserved in all of the six staphylococcal genomes currently sequenced and the remaining two are present in 5/6 of these genomes.
  • In accordance with the invention, amino acid and nucleic acid sequences coding for the above proteins were obtained, and these were as follows: Ekes MRSA—SEQ ID NO:1 (DNA sequence); EkeS_MRSA—SEQ ID NO:2 (Protein sequence); DsqA (8325)—SEQ ID NO:3 (DNA sequence); DsqA (8325)—SEQ ID NO:4 (Protein sequence); KesK1 (8325)—SEQ ID NO:5 (DNA sequence); KesK1 (8325)—SEQ ID NO:6 (Protein sequence); KrkN2 (8325)—SEQ ID NO:7 (DNA sequence); KrkN2 (8325)—SEQ ID NO:8 (Protein sequence); KrkN (8325)—SEQ ID NO:9 (DNA sequence); KrkN (8325)—SEQ ID NO:10 (Protein sequence); RkaS (COL)—SEQ ID NO:11 (DNA sequence); RkaS (COL)—SEQ ID NO:12 (Protein sequence); RrkN (8325)—SEQ ID NO:13 (DNA sequence); RrkN (8325)—SEQ ID NO:14 (Protein sequence); KnkA (8325)—SEQ ID NO:15 (DNA sequence); KnkA (8325)—SEQ ID NO:16 (Protein sequence).
  • In accordance with the present invention, isolated antibodies may be generated from the above proteins or their active regions such as the A domain so as to be able to recognize said proteins and/or said domains. These antibodies may be either monoclonal or polyclonal. If polyclonal antibodies are desired, these may be generated in any of a number of conventional ways well known in the art. In a typical process, the desired surface protein or active region thereof may be injected into a suitable host animal, e.g., a mouse or rabbit, and after a suitable time period, antibodies may be isolated and recovered from the host animal. With regard to monoclonal antibodies, in accordance with the present invention, these may be produced in any number of suitable ways including, e.g., the well known method of Kohler and Milstein, Nature 256:495-497 (1975), or other suitable ways known in the field, such as those methods disclosed in U.S. Pat. Nos. 6,331,415; 5,981,216; 5,807,715; and 4,816,567; Eur. Pat. App. 519,596; and PCT publication WO 00/71585, all of these patent publications incorporated herein by reference. These methods include their preparation as chimeric, humanized, or human monoclonal antibodies in ways that would be well known in this field. Still further, monoclonal antibodies may be prepared from a single chain, such as the light or heavy chains, and in addition may be prepared from active fragments of an antibody which retain the binding characteristics (e.g., specificity and/or affinity) of the whole antibody. By active fragments is meant an antibody fragment which has the same binding specificity as a complete antibody which binds to the particular surface protein or its homologue from the different type of staph bacteria (i.e., coagulase negative or coagulase-positive), and the term “antibody” as used herein is meant to include said fragments. Additionally, antisera prepared using monoclonal or polyclonal antibodies in accordance with the invention are also contemplated and may be prepared in a number of suitable ways as would be recognized by one skilled in the art.
  • As indicated above, antibodies to the isolated surface proteins and/or their active regions in accordance with the invention may be prepared in a number of suitable ways that would be well known in the art, such as the well-established Kohler and Milstein method described above which can be utilized to generate monoclonal antibodies. For example, in preliminary steps utilized in such a process, mice may be injected intraperitoneally once a week for a prolonged period with a purified recombinant MSCRAMM® in accordance with the invention or an active portion thereof, followed by a test of blood obtained from the immunized mice to determine reactivity to the purified protein. Following identification of mice reactive to the proteins, lymphocytes isolated from mouse spleens are fused to mouse myeloma cells to produce hybridomas positive for the antibodies against the surface proteins of the invention which are then isolated and cultured, following by purification and isotyping.
  • In order to generate monoclonal antibodies in accordance with the invention, it is preferred that these be generated using recombinantly prepared MSCRAMM®'s in accordance with the invention, and these recombinants may be generated and isolated using a number of standard methods well known in the art. For example, one such method employs the use of E. coli expression vector pQE-30 as an expression vector for cloning and expressing recombinant proteins and peptides. In one preferred method, using PCR, the A domain of the surface protein identified as DgsK or SasA was amplified from the sequences described above and subcloned into the E. coli expression vector PQE-30 (Qiagen), which allows for the expression of a recombinant fusion protein containing six histidine residues. This vector was subsequently transformed into E. coli strain ATCC 55151, grown in a 15-liter fermentor to an optical density (OD600) of 0.7 and induced with 0.2 mM isopropyl-1-beta-D galactoside (IPTG) for 4 hours. The cells were harvested using an AG Technologies hollow-fiber assembly (pore size 0.45 μm) and the cell paste frozen at −80° C. Cells were lysed in 1×PBS (10 mL buffer/1 g of cell paste) using 2 passes through the French Press @ 1100 psi. Lysed cells were spun down at 17,000 rpm for 30 minutes to remove cell debris. Supernatant was passed over a 5-mL HiTrap Chelating (Pharmacia) column charged with 0.1M NiCl2. After loading, the column was washed with 5 column volumes of 10 mM Tris, pH 8.0, 100 mM NaCl (Buffer A). Protein was eluted using a 0-100% gradient of 10 mM Tris, pH 8.0, 100 mM NaCl, 200 mM imidazole (Buffer B) over 30 column volumes. SdrGNlN2N3 or SdrGN2N3 eluted at ˜13% Buffer B (˜26mM imidazole). Absorbance at 280nm was monitored. Fractions containing SdrGN1N2N3 or SdrGN2N3 were dialyzed in 1×PBS.
  • Next, each protein was then put through an endotoxin removal protocol. Buffers used during this protocol were made endotoxin free by passing over a 5-mL Mono-Q sepharose (Pharmacia) column. Protein was divided evenly between 4×15 mL tubes. The volume of each tube was brought to 9 mL with Buffer A. 1 mL of 10% Triton X-114 was added to each tube and incubated with rotation for 1 hour at 4° C. Tubes were placed in a 37° C. water bath to separate phases. Tubes were spun down at 2,000 rpm for 10 minutes and the upper aqueous phase from each tube was collected and the detergent extraction repeated. Aqueous phases from the 2nd extraction were combined and passed over a 5-mL IDA chelating (Sigma) column, charged with 0.1M NiCl2 to remove remaining detergent. The column was washed with 9 column volumes of Buffer A before the protein was eluted with 3 column volumes of Buffer B. The eluant was passed over a 5-mL Detoxigel (Sigma) column and the flow-through collected and reapplied to the column. The flow-through from the second pass was collected and dialyzed in 1×PBS. The purified product was analyzed for concentration, purity and endotoxin level before administration into the mice.
  • In the preferred process, monoclonal antibodies in accordance with the present invention may be prepared from the recombinant proteins identified above in the following manner. In this process, E. coli expressed and purified recombinant SasA and DsgK proteins were used to generate a panel of murine monoclonal antibodies while the mouse sera was used as a source of polyclonal antibodies. Briefly, a group of Balb/C or SJL mice received a series of subcutaneous immunizations of 1-10 mg of protein in solution or mixed with adjuvant as described below in Table 2.
    TABLE 2
    Immunization Schemes
    Day Amount (μg) Route Adjuvant
    RIMMS
    Injection
    #
    1 0 5 Subcutaneous FCA/RIBI
    #
    2 2 1 Subcutaneous FCA/RIBI
    #
    3 4 1 Subcutaneous FCA/RIBI
    #
    4 7 1 Subcutaneous FCA/RIBI
    #
    5 9 1 Subcutaneous FCA/RIBI
    Conventional
    Injection
    Primary
    0 5 Subcutaneous FCA
    Boost #
    1 14 1 Intraperitoneal RIBI
    Boost #
    2 28 1 Intraperitoneal RIBI
    Boost #
    3 42 1 Intraperitoneal RIBI
  • At the time of sacrifice (RIMMS) or seven days after a boost (conventional) serum was collected and titered in ELISA assays against MSCRAMM® proteins or on whole cells (S. epidermidis and S. aureus). Three days after the final boost, the spleens or lymph nodes were removed, teased into a single cell suspension and the lymphocytes harvested. Lymphocytes were then fused to a P3X63Ag8.653 myeloma cell line (ATCC #CRL-1580). Cell fusion, subsequent plating and feeding were performed according to the Production of Monoclonal Antibodies protocol from Current Protocols in Immunology (Chapter 2, Unit 2.), incorporated herein by reference.
  • Any clones that were generated from the fusion were then screened for specific anti-SasA antibody production using a standard ELISA assay. Positive clones were expanded and tested further for activity in a whole bacterial cell binding assay by flow cytometry and SasA binding by Biacore analysis. Throughout the Biacore analysis, the flow rate remained constant at 10 ml/min. Prior to the SasA or DgsK injection, test antibody was adsorbed to the chip via RAM-Fc binding. At time 0, SasA or DgsK at a concentration of 30 mg/ml was injected over the chip for 3 min followed by 2 minutes of dissociation. This phase of the analysis measured the relative association and disassociation kinetics of the Mab/SasA or DgsK interaction.
  • Next, the antibodies prepared as set forth above were tested for binding to whole bacteria. In these tests, bacterial samples S. aureus Newman, S. aureus 67-0, S. aureus 397 (Sal6), S. aureus Wood, S. aureus 8325-4, methicillin resistant S. aureus MRSA 16, S. epidermidis ATCC 35984, S. epidermidis HB, S. epidermidis CN-899 and S. haemolyticus ATCC 43253 were collected, washed and incubated with Mab or PBS alone (control) at a concentration of 2 μg/ml after blocking with rabbit IgG (50 mg/ml). Following incubation with antibody, bacterial cells were incubated with Goat-F(ab′)2-Anti-Mouse-F(ab′)2-FITC which served as the detection antibody. After antibody labeling, bacterial cells were aspirated through the FACScaliber flow cytometer to analyze fluorescence emissipon (excitation: 488, emission: 570). For each bacterial strain, 10,000 events were collected and measured. These data indicate that antibodies against S. aureus SasA were able to recognize a homologous protein on the surface of coagulase-negative staphylococci. The data support Western blot analysis demonstrating that rabbit polyclonal antibodies against S. aureus SasA cross-react with a protein released from the cell surface of S. epidermidis HB as well as the recombinant A-region from DsgK cloned from S. epidermidis (see FIG. 6 and Table 3 below).
    TABLE 3
    Polyclonal Sera Reactivity
    397
    (SAL Wood MRSA ATCC CN- ATCC
    Newman 67-0 6) 46 8325-4 16 35984 HB 899 43253
    Normal − − − − − − − − − −
    Mouse
    Sera
    Mouse + + +/− − + + + + + +
    anti-
    SasA
  • Although production of antibodies using recombinant forms of the surface proteins of the present invention is preferred, antibodies may be generated from natural isolated and purified versions of these proteins or their active regions such as the A domain, and monoclonal or polyclonal antibodies can be generated using these proteins or active regions in the same manner as described above to obtain such antibodies. Still other conventional ways are available to generate the antibodies of the present invention using recombinant or natural purified proteins or their active regions, as would be recognized by one skilled in the art.
  • As would be recognized by one skilled in the art, the antibodies of the present invention may also be formed into suitable pharmaceutical compositions for administration to a human or animal patient in order to treat or prevent an infection caused by staphylococcal bacteria. Pharmaceutical compositions containing the antibodies of the present invention, or effective fragments thereof, may be formulated in combination with any suitable pharmaceutical vehicle, excipient or carrier that would commonly be used in this art, including such as saline, dextrose, water, glycerol, ethanol, other therapeutic compounds, and combinations thereof. As one skilled in this art would recognize, the particular vehicle, excipient or carrier used will vary depending on the patient and the patient's condition, and a variety of modes of administration would be suitable for the compositions of the invention, as would be recognized by one of ordinary skill in this art. Suitable methods of administering any pharmaceutical composition disclosed in this application include, but are not limited to, topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal and intradermal administration.
  • For topical administration, the composition is formulated in the form of an ointment, cream, gel, lotion, drops (such as eye drops and ear drops), or solution (such as mouthwash). Wound or surgical dressings, sutures and aerosols may be impregnated with the composition. The composition may contain conventional additives, such as preservatives, solvents to promote penetration, and emollients. Topical formulations may also contain conventional carriers such as cream or ointment bases, ethanol, or oleyl alcohol. Additional forms of antibody compositions, and other information concerning compositions, vaccines, methods and applications with regard to other MSCRAMM®s will generally also be applicable to the present invention involving the aforementioned MSCRAMM®s and their active regions and antibodies thereto, and these other MSCRAMM®s are disclosed, for example, in U.S. Pat. Nos. 5,175,096; 5,320,951; 5,416,021; 5,440,014; 5,571,514; 5,652,217; 5,707,702; 5,789,549; 5,840,846; 5,980,908; 6,086,895; 6,008,341; 6,177,084; 5,851,794 and 6,288,214; all of these patents incorporated herein by reference.
  • The antibody compositions of the present invention may also be administered with a suitable adjuvant in an amount effective to enhance the immunogenic response. For example, suitable adjuvants may include alum (aluminum phosphate or aluminum hydroxide), which is used widely in humans, and other adjuvants such as saponin and its purified component Quil A, Freund's complete adjuvant, RIBBI adjuvant, and other adjuvants used in research and veterinary applications. Still other chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. J. Immunol. 147:410415 (1991) and incorporated by reference herein, encapsulation of the conjugate within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992) and incorporated by reference herein, and encapsulation of the protein in lipid vesicles such as Novasome™ lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.) may also be useful.
  • In any event, the antibody compositions of the present invention which recognize the proteins or their active regions as set forth above will be useful in methods of preventing or treating staphylococcal infection, and in inhibiting binding of staphylococcal bacteria to host tissue and/or cells. In accordance with the present invention, methods are provided for preventing or treating a staphylococcal infection which comprise administering an effective amount of an antibody to the surface proteins as set forth herein or their active subregions so as to treat or prevent a staphylococcal infection. In addition, these monoclonal antibodies will be useful in impairing the binding of staphylococcal bacteria to host cells
  • Accordingly, in accordance with the invention, administration of the antibodies of the present invention in any of the conventional ways described above (e.g., topical, parenteral, intramuscular, etc.), and will thus provide an extremely useful method of treating or preventing staphylococcal infections in human or animal patients when an effective amount of the antibody compositions are administered to a human or animal patient. By effective amount is meant that level of use, such as of an antibody titer, that will be sufficient to either prevent adherence of the bacteria, to inhibit binding of staph bacteria to host cells and thus be useful in the treatment or prevention of a staph infection. As would be recognized by one of ordinary skill in this art, the level of antibody titer needed to be effective in treating or preventing staphylococcal infection will vary depending on the nature and condition of the patient, and/or the severity of the pre-existing staphylococcal infection.
  • In addition to use in methods or treating or preventing a staphylococcal infection, the antibodies of the invention may also be used for the specific detection of staphylococcal proteins, or as research tools. The term “antibodies” as used herein includes monoclonal, polyclonal, chimeric, single chain, bispecific, simianized, and humanized or primatized antibodies as well as Fab fragments, such as those fragments which maintain the binding specificity of the antibodies to the surface proteins specified above, including the products of an Fab immunoglobulin expression library. Accordingly, the invention contemplates the use of single chains such as the variable heavy and light chains of the antibodies. Generation of any of these types of antibodies or antibody fragments is well known to those skilled in the art. In the present case, antibodies to the surface proteins or their active regions as referred to above can be generated, isolated and/or purified, and then used to treat or protect against staphylococcal infection.
  • Any of the above described antibodies may be labeled directly with a detectable label for identification and quantification of staph bacteria. Labels for use in immunoassays are generally known to those skilled in the art and include enzymes, radioisotopes, and fluorescent, luminescent and chromogenic substances, including colored particles such as colloidal gold or latex beads. Suitable immunoassays include enzyme-linked immunosorbent assays (ELISA).
  • Alternatively, the antibody may be labeled indirectly by reaction with labeled substances that have an affinity for immunoglobulin. The antibody may be conjugated with a second substance and detected with a labeled third substance having an affinity for the second substance conjugated to the antibody. For example, the antibody may be conjugated to biotin and the antibody-biotin conjugate detected using labeled avidin or streptavidin. Similarly, the antibody may be conjugated to a hapten and the antibody-hapten conjugate detected using labeled anti-hapten antibody. These and other methods of labeling antibodies and assay conjugates are well known to those skilled in the art.
  • In accordance with the present invention, there are also provided vaccines for either active or passive immunization designed to treat or protect against staphylococcal infections, and these vaccines may be prepared from the surface proteins or their active regions as set forth above using a number of the conventional vaccine preparation methods well known in this field. In the typical vaccine, an immunogenic amount of a suitable surface protein or active fragment thereof is combined with a suitable pharmaceutically acceptable vehicle, carrier or excipient, and an amount of this vaccine effective to immunize a human or animal patient may be administered as appropriate. By immunogenic amount it would be understood by one of ordinary skill in this art that this refers to any amount of the protein or active fragment or subregion thereof which is able to raise an immunogenic response in the human or animal patient.
  • In addition to active vaccines wherein antibodies are generated in the patient by virtue of the introduction or administration of an immunogenic amount of a protein or active fragment in accordance with the present invention, the isolated antibodies of the present invention, or active fragments thereof, may also be utilized in the development of vaccines for passive immunization against staph infections. In such a case, the antibody compositions as described above, namely an effective amount of the antibody and a pharmaceutically acceptable vehicle, carrier or excipient, may be administered as appropriate to a human or animal patient.
  • Accordingly, in accordance with the invention, the proteins or active fragments thereof may be utilized as active vaccines, and the antibodies of the invention may be used as a passive vaccine which will be useful in providing suitable antibodies to treat or prevent a staphylococcal infection. As would be recognized by one skilled in this art, a vaccine may be packaged for administration in a number of suitable ways, such as by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration. One such mode is where the vaccine is injected intramuscularly, e.g., into the deltoid muscle, however, the particular mode of administration will depend on the nature of the bacterial infection to be dealt with and the condition of the patient. The vaccine is preferably combined with a pharmaceutically acceptable vehicle, carrier or excipient to facilitate administration, and the carrier is usually water or a buffered saline, with or without a preservative. The vaccine may be lyophilized for resuspension at the time of administration or in solution.
  • In addition, in certain cases, the antibodies of the present invention may be modified as necessary so that, when necessary, they become less immunogenic in the patient to whom it is administered. For example, if the patient is a human, the antibody may be “humanized” by transplanting the complimentarity determining regions of the hybridoma-derived antibody into a human monoclonal antibody as described, e.g., by Jones et al., Nature 321:522-525 (1986) or Tempest et al. Biotechnology 9:266-273 (1991) or “veneered” by changing the surface exposed murine framework residues in the immunoglobulin variable regions to mimic a homologous human framework counterpart as described, e.g., by Padlan, Molecular Imm. 28:489-498 (1991), these references incorporated herein by reference. Even further, when so desired, the monoclonal antibodies of the present invention may be administered in conjunction with a suitable antibiotic to further enhance the ability of the present compositions to fight bacterial infections when necessary.
  • In addition to treating human or animal patients, the present compositions may also be used to halt or prevent infection of a medical device or other biomaterials such as an implant. Medical devices or polymeric biomaterials to be coated with the antibodies, proteins and active fragments described herein include, but are not limited to, staples, sutures, replacement heart valves, cardiac assist devices, hard and soft contact lenses, intraocular lens implants (anterior chamber or posterior chamber), other implants such as corneal inlays, kerato-prostheses, vascular stents, epikeratophalia devices, glaucoma shunts, retinal staples, scleral buckles, dental prostheses, thyroplastic devices, laryngoplastic devices, vascular grafts, soft and hard tissue prostheses including, but not limited to, pumps, electrical devices including stimulators and recorders, auditory prostheses, pacemakers, artificial larynx, dental implants, mammary implants, penile implants, cranio/facial tendons, artificial joints, tendons, ligaments, menisci, and disks, artificial bones, artificial organs including artificial pancreas, artificial hearts, artificial limbs, and heart valves; stents, wires, guide wires, intravenous and central venous catheters, laser and balloon angioplasty devices, vascular and heart devices (tubes, catheters, balloons), ventricular assists, blood dialysis components, blood oxygenators, urethral/ureteral/urinary devices (Foley catheters, stents, tubes and balloons), airway catheters (endotracheal and tracheostomy tubes and cuffs), enteral feeding tubes (including nasogastric, intragastric and jejunal tubes), wound drainage tubes, tubes used to drain the body cavities such as the pleural, peritoneal, cranial, and pericardial cavities, blood bags, test tubes, blood collection tubes, vacutainers, syringes, needles, pipettes, pipette tips, and blood tubing.
  • It will be understood by those skilled in the art that the term “coated” or “coating”, as used herein, means to apply the antibody or active fragment, or pharmaceutical composition derived therefrom, to a surface of the device, preferably an outer surface that would be exposed to streptococcal bacterial infection. The surface of the device need not be entirely covered by the protein, antibody or active fragment.
  • The preferred dose for administration of an antibody composition in accordance with the present invention is that amount will be effective in preventing of treating a staphylococcal infection, and one would readily recognize that this amount will vary greatly depending on the nature of the infection and the condition of a patient. As indicated above, an “effective amount” of antibody or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the agent, such that the desired prophylactic or therapeutic effect is produced. As will be pointed out below, the exact amount of the antibody or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like. Accordingly, the “effective amount” of any particular antibody composition will vary based on the particular circumstances, and an appropriate effective amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual. The compositions may also contain stabilizers or pharmaceutically acceptable preservatives, such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, Mo.).
  • When used with suitable labels or other appropriate detectable biomolecule or chemicals, the monoclonal antibodies described herein are useful for purposes such as in vivo and in vitro diagnosis of staphylococcal infections or detection of staphylococcal bacteria. Laboratory research may also be facilitated through use of such antibodies. Various types of labels and methods of conjugating the labels to the antibodies of the invention are well known to those skilled in the art, such as the ones set forth below.
  • For example, the antibody can be conjugated (directly or via chelation) to a radiolabel such as, but not restricted to, 32P, 3H, 14C, 35S, 125I, or 131I. Detection of a label can be by methods such as scintillation counting, gamma ray spectrometry or autoradiography. Bioluminescent labels, such as derivatives of firefly luciferin, are also useful. The bioluminescent substance is covalently bound to the protein by conventional methods, and the labeled protein is detected when an enzyme, such as luciferase, catalyzes a reaction with ATP causing the bioluminescent molecule to emit photons of light. Fluorogens may also be used to label proteins. Examples of fluorogens include fluorescein and derivatives, phycoerythrin, allo-phycocyanin, phycocyanin, rhodamine, and Texas Red. The fluorogens are generally detected by a fluorescence detector.
  • The location of a ligand in cells can be determined by labeling an antibody as described above and detecting the label in accordance with methods well known to one skilled in the art, such as immunofluorescence microscopy using procedures such as those described by Warren et al. (Mol. Cell. Biol., 7: 1326-1337, 1987).
  • As indicated above, the monoclonal antibodies of the present invention, or active portions or fragments thereof, are particularly useful for interfering with the initial physical interaction between a staphylococcal pathogen responsible for infection and a mammalian host, and this interference with the physical interaction may be useful both in treating patients and in preventing or reducing bacteria infection on in-dwelling medical devices to make them safer for use.
  • In another embodiment of the present invention, a kit which may be useful in isolating and identifying staphylococcal bacteria and infection is provided which comprises the antibodies of the present invention in a suitable form, such as lyophilized in a single vessel which then becomes active by addition of an aqueous sample suspected of containing the staphylococcal bacteria. Such a kit will typically include a suitable container for housing the antibodies in a suitable form along with a suitable immunodetection reagent which will allow identification of complexes binding to the surface proteins or the antibodies of the invention. In general, these kits may contain an antibody in accordance with the invention and means to identify binding of that antibody when a sample from a patient is introduced to the antibody. For example, a suitable immunodetection reagent may comprise an appropriate detectable signal or label, such as a biotin or enzyme that produces a detectable color, etc., which may be linked to the antibody or utilized in other suitable ways so as to provide a detectable result when the antibody binds to the antigen.
  • In short, the antibodies of the preset invention which recognize and bind to the surface proteins of the invention, or active fragments thereof, will thus be useful in treating a wide variety of staphylococcal infections in human and animal patients and in medical or other in-dwelling devices. In accordance with the invention, because of the nature of these proteins and the fact that they contain epitopes in common with proteins of the other type of staphylococcal bacteria, i.e., a protein from a coagulase-negative staph will raise antibodies that recognize a homologous protein from S. aureus and vice versa, the antibodies of the invention will exhibit cross-reactivity and should be effective against a broad range of staphylococcal infections. Accordingly, the present invention provides methods and compositions for improved methods of treating or protecting against a wide range of staphylococcal infections.
    • EXAMPLES
  • The following examples are provided which exemplify aspects of the preferred embodiments of the present invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
    • Example 1 Isolation and Sequencing of MSCRAMM's from S. Aureus
  • Staphylococcus aureus is known to express a class of surface-associated proteins which play important roles in pathogenicity by allowing bacteria to avoid host defenses and by acting as adhesins. These proteins are known as MSCRAMMs (Microbial Surface Components Recognizing Adhesive Matrix Molecules) and in most cases are covalently anchored to the cell wall peptidoglycan. They have several common features: (i) an N-terminal signal peptide (approximately 40 residues in length) required for Sec-dependent secretion, (ii) a wall spanning domain either rich in proline and glycine residues or composed of serine and aspartate dipeptide repeats, (iii) an LPXTG motif required for covalent anchoring of the protein to the pentaglycine crossbridge in peptidoglycan, (iv) a hydrophobic membrane-spanning domain followed by (v) several positively charged residues.
  • By exploiting the whole genome sequences of S. aureus, eight novel open reading frames encoding proteins with secretion and anchorage motifs indicative of MSCRAMMs were identified (i.e. bearing an N-terminal signal peptide and a C-terminal LPXTG motif followed by a hydrophobic domain and a positively charged tail). The following Table illustrates the list of proteins identified including their distribution among S. aureus genomes, their protein size and C-terminal cell wall sorting sequence.
    Name Distribution Size C-terminus
    EkeS ENCSJM  2189 aa LPNTGSEEMDLPLKELALITGAALLARRRS
    KKEKES
    DsqA ENCSJM ˜1363- LPDTGDSIKQNGLLGGVMTLLVGLGLMKR
     2283 aa KKKKDENDQDDSQA
    KesK ENCSJM  ˜909 aa LPKTGETTSSQSWWGLYALLGMLALFIPK
    FRKESK
    KrkN2 ENCSJM  ˜278 aa LPKTGLTSVDNFISTVAFATLALLGSLSLLLF
    (Cowan) KRKESK
    KrkN ENCSJM  ˜661 aa LPQTGEESNKDMTLPLMALIALSSIVAFVLP
    RKRKN
    RkaS ENCSJM  ˜801 aa LPKTGTNQSSSPEAMFVLLAGIGLIATVRR
    RKAS
    RrkN NCSJM  1629 aa LPKTGLESTQKGLIFSSIIGIAGLMLLARRRK
    N
    KnkA NCSJM  629 aa LPKAGETIKEHWLPISVIVGAMGVLMIWLS
    RRNKLKNKA

    Abbreviations: eMRSA-16; N, 8325; C, COL; S, MSSA; J, N315, M, Mu50. Six out of eight are conserved in all of the six staphylococcal genomes currently sequenced and the remaining two are present in 5/6 of these genomes.
  • The following is a list of the DNA and protein sequences:
    Ekes MRSA
    acaacacagcagagaatagacaaccaggaggaaaacgaaatgaatttgttaaagaaaaataaatatagtattag (SEQ ID NO:1)
    aaaatataaagtagggatattctctactttaatcgggacagttttattactttcaaacccaaatggtgcacaagctttaac
    tacggatcataatgtgcaaggtggttcaaatcaagcattacctggcaactcacaaaatacaaatgccgatactaatc
    gagacatagtaaatgattcgcaaaatactcctaatgcacatgcaacagacaatacatcaacaaatcaagcattgac
    taatcatcaaaacgttgatgtggcaaatcaagtcgggcctgctccaatacagcctagcgcgtcgcctgcgcaaaata
    ataataattctaatgctaattcaacagcaacagagccagcggcgaatacaaataataatttagcatcaaataacaat
    acattaaacgtgcctaataatacagataacaatgattcagcgcgtcatctgactttaaaagaaattcaagaagatgtt
    cgtcattcgtctgataagccagagttagttgcgattgctgaagaagcatctaatagaccgaaaaagagaagcagac
    gtgctgcgccaacagatcctaatgcaacaccagcagatccaacggctacaccagcagatccaacggcaggaaat
    ggtagtgcaccagttgcaattacagcgccatacacgccaacaactgatcccaatgccaataatataggacaaaatg
    cacctaacgaagtgctttcatttgatgataacaacattagaccaagtacgaaccgttctgtgcctacagtaactgttgtt
    gataatttaccaggctacacactgattaatggtggtaaagtaggggtgtttagtcatgcaatggtaagaacgagcatgt
    ttgattcaggagatgccaagaactatcaagcgcaaggcaatgtaattgcattgggtcgtattagaggaaatgataca
    aatgatcatggcgattttaatggtatcgagaaaacattaacagtaaatccgaattctgaattaatctttgaatttaatact
    atgactactaaaaactatcaaggtatgacaaatttaatcattaaaaatgctgataacgatactgttattggtgaaaaag
    tagttgcttatggtccgatttggcgcttattaaaagtacctgaaaatgttagtcatctaaaaattcaatttgtacctaaaaat
    gacgcaataacagatgcacgtggtatttatcaattacgagatggatataaatactatgactttgtagactcaatcggtct
    tcattctgggtcacatgtctatgttgaaagacgtacaatggagccaacagcaacaaataataaagaatttacagttac
    aacgtcattaaagaataatggtaactttggcgcttcattcaatacagatgattttgtatataaaattcaattacctgaaggt
    gttgaatatgtaaataattcattgactaaagattttcctagcggtaattcaggtgttgatattaatgatatgaatgtgacgta
    tgacgcagcaaatcgaattattacaattaaaagtactggtggaggtacagggaattcgccggcacgactaatgcctg
    ataaaatattggatttgaagtataagctacgtgtgaacaatgtgccaacaccaagaacagtaacatttaacgatacat
    taacgtataaaacatattcacaagattttattaattcacctgctgaaagtcatactgtaagtacaaatccatatacaattg
    atatcatcatgaataaagacgcattgcaagccgaagtcgatagacgaattcaacaagcggattatacatttgcatcat
    tagatatttttaatgatcttaaaagacgcgcacaaacaattttagatgaaaaccgtaacaatgtacctttaaacaaaag
    agtttctcaagcagatatcgattcattagcaaatcagatgcaacatacgttaattcgcagtgttgacgctgaaaatgcc
    gttaatagaaaagttgatgacatggaagatttagttaaccaaaatgatgaactgacagatgaagaaaaacaagca
    gcgattcaagtcatcgaggaacataaaaatgaaattattgggaatattggtgaccaaacgactgatgatggcgttact
    agaattaaagatcaaggtatacagactttaagtggagacactgcaacaccagttgttaaaccaaatgctaaacaag
    ctatacgtgataaagcagcgaaacaaagagaaattatcaatcacacgccagatgctactcaagatgaaattcaag
    atgcattaaatcaattaacaacggatgaaacagatgctattgataatgttacgaatgctactaccaatgctgatgttga
    aacagctaaaaataatggtattaatacaattggtgcagttgcgccacaagtgacacacaaacaagctgcaagaga
    tgcaattaatcaagcgacagcaacgaaacgacaacaaataaatagcaatagagaagcaacacaagaagaga
    aaaatgcagcattgaatgaattaacgcaagccacgaaccacgcattagaacaaatcaatcaagcgacaaccaat
    gatgatgtagatactgccaaaggtgatggtctgaatgccattaatcctattgcgcctgtaactgttgtcaagcaagcag
    caagagatgccgtatcacatgatgcacaacagcatatcgcagagatcaatgcaaatcctgatgcgactcaagaag
    aaagacaagcagcaatagagaaagtaaatgctgctgtagctgttgcgaatactaatatattaaatgctaataccaat
    gctgatgttgagcaagtaaagacaaatgcaattcaaggtatacaagccattgaaccagctacaaaggttaaaaca
    gatgctaaaaacgctattgatcaaagtgcggaaacgcaacataatgcgatatttaataataatgatgcgaccttaga
    agagcaacaagcagcacaacaattgcttgatcaagctgtagccacagcgaagcaaaatattaatgcagcagata
    cgaatcaagaagttgcacaagcaaaagatcagggcacacaaaatatagttgtgattcaaccggcaacacaagtta
    aaacggatgcacgcaatgctgtaaatgaaaaagcgcgagaggcgataacaaatatcaatgctacacctggcgcg
    actcgagaagagaaacaagaagcgataaatcgtgtcaatacacttaaaaatagagcattaaatgatattggtgtga
    cgtctactactgcgatggtcaatagtattagagacgatgcagtcaatcaaatcggtgcagttcaaccgcatgtaacga
    agaaacaaactgctacaggtgtattaacggacttagcaactgcaaaaaaacaagaaattaatcaaaatacaaatg
    caaccactgaagaaaagcaagtagcattaaatcaagtagaccaagatttagcaacggcaattaataatataaatc
    aagctgatactaatgcagaagtagatcaagcacaacaattaggtacaaaagcaattaatgcgattcagccaaatat
    tgtaaaaaaacctgcagcattagcacaaaccaatcagcattatagtgctaaattagttgaaatcaatgctacaccag
    atgcaacagatgatgagaaaaatgctgcgatcaatactttaaatcaagacagacaacaagctattgaaagtattaa
    acaagcaaatacaaatgcggaagtagaccaagctgcgacagtggcagagaataatatcgatgctgttcaagttga
    cgttgtaaaaaaacaagcagcgcgagataaaatcactgctgaagtagcgaagcgtattgaagcggttaaacaaa
    cacctaatgcaactgacgaagaaaagcaggctgcagttaatcaaatcaatcaacttaaagatcaagcgtttaatca
    aattaatcaaaaccaaacaaatgatcaggtagacgcaactacaaatcaagcgattaatgctatagataatgttgaa
    gctgaagtagtaattaaaccaaaggcaattgcagatattgaaaaagctgttaaagaaaagcaacagcaaattgat
    aatagtcttgattcaacagataatgagaaagaagttgctttacaagcattagctaaagaaaaagaaaaagcacttg
    cagctattgaccaagctcaaacgaatagtcaggtgaatcaagcggcaacaaatggtgtatcagcgattaaaattatt
    caacctgaaacaaaaattaaaccagcagcacgtgaaaaaatcaatcaaaaagcgaatgaattacgtgcgcaaa
    ttaatcaagataaagaagcgacagcagaagaaagacaagcggcgttagataaaatcaatgatttagttgctaaag
    ctatgacaaatatcacgaatgatagaacaaatcagcaagttaatgactcaacaaatcaagcgcttgacgacattgc
    attagtgacgcctgaccatattgttagagcagctgctagagatgcagttaagcaacaatatgaagctaaaaagcac
    gaaattgagcaagcggaacatgcgactgatgaagaaaaacaagttgctttaaatcaattagcgaataatgaaaaa
    cgtgcattacaaaacattaatcaagcaatagcgaataatgatgtgaaacgtgttgaatcaaatggtattgctacgttaa
    aaggcgtagaaccgcacattgtggttaaacctgaagctcaagaagccataaaagcgagcgcagataaccaagta
    gaatctataaaagatacaccacatgctacgacagatgaattagatgaagcaaaccaacaaataaacgacacactt
    aaacaaggtcaacaagatatagacaatacgacacaagatgcagctgtcaatgatgttagaaaccaaacgattaa
    ggcaatcgaacaaattaaaccgaaagttagacgcaaacgtgcagcgttggataacattgatgaaagtaataataat
    caactcgatgcaatacgaaatacgctagatacaacgcaagatgaacgaaatgttgctattgctgcgttaaataaaat
    tgttaatgcaattaaaaatgatattgcacaaaacaaaacgaatgcagaagtggatcaaactgaggctgatggtaac
    aacaacatcaaagtgattttacctaaagttcaagttaaaccagcagcgcgtcaatctgtcagcgcaaaagctgaag
    ctcaaaatgcacttattgatcaaagtgatttatctaccgaagaagaaagattagctgctaaacatttagtagaacaag
    cacttaatcaagctattgatcagatcaatcacgcagataagactgcgcaagttaatcaaaatagtatcgatgctcaaa
    atattatttcaaaaattaaaccagcgacaacagttaaagcaacagcattacaacaaattcaaaatatcgctacaaat
    aaaattaatttaattaaagcaaataacgaagcgacagatgaagaacaaaatgctgcaatagtacaagttgaaaaa
    gagttaattaaagctaaacaacaaattgctggtgcagtgactaatgctgatgtggcatatttattgcatgatgggaaaa
    acgaaattcgtgaaatcgaacctgttattaataaaaaagcaactgcgcgagaacaattaacaacattattcaacgat
    aagaaacaagcaattgaagcgaatgttcaagcaacagtagaagaaagaaatagtattttagcacagttacaaaa
    catttatgacactgctattggacaaattgatcaagatcgtagcaatgcacaagttgataaaacagcaacattaaatct
    acaaacaatacatgatttagacgtacatcctattaaaaagccagatgctgaaaaaacgattaatgatgatcttgcac
    gtgttacacatttagtgcaaaattatcgaaaagtaagtgatcgtaataaggctgatgcattaaaagctataactgcatt
    aaaattacaaatggatgaagaattaaaaacagcacgcactaatgctgatgttgatgcagttttaaaacgatttaatgtt
    gcattaggcgatatagaagcagtaattactgaaaaagaaaatagcttactgcgcattgataacattgctcaacaaac
    atatgcgaaattcaaagcgatcgcaacaccagaacaattagctaaagtaaaagcattaattgatcaatatgttgcag
    atggcaatagaatggttgatgaagatgcgacattaaatgacatcaaaaaagatacgcaactcattattgatgaaattt
    tagcaattaaattacctgctgaagtgataaaagcgtcaccaaaagtggggcaacctgctccaaaagtttgtacgcct
    attaaaaaagaagataaacaagaagtgcgaaaagttgtaaaagaacttccaaatactggttctgaagaaatggatt
    taccattaaaagaattagcactaattacaggcgcagcattattagctagaagacgttctaaaaaagaaaaagaatc
    ataa
    EkeS_MRSA
    MNLLKKNKYSIRKYKVGIFSTLIGTVLLLSNPNGAQALTTDHNVQGGSNQALPGNS (SEQ ID NO:2)
    QNTNADTNRDIVNDSQNTPNAHATDNTSTNQALTNHQNVDVANQVGPAPIQPSA
    SPAQNNNNSNANSTATEPAANTNNNLASNNNTLNVPNNTDNNDSARHLTLKEIQE
    DVRHSSDKPELVAIAEEASNRPKKRSRRAAPTDPNATPADPTATPADPTAGNGSA
    PVAITAPYTPTTDPNANNIGQNAPNEVLSFDDNNIRPSTNRSVPTVTVVDNLPGYTL
    INGGKVGVFSHAMVRTSMFDSGDAKNYQAQGNVIALGRIRGNDTNDHGDFNGIEK
    TLTVNPNSELIFEFNTMTTKNYQGMTNLIIKNADNDTVIGEKVVAYGPIWRLLKVPE
    NVSHLKIQFVPKNDAITDARGIYQLRDGYKYYDFVDSIGLHSGSHVYVERRTMEPT
    ATNNKEFTVTTSLKNNGNFGASFNTDDFVYKIQLPEGVEYVNNSLTKDFPSGNSG
    VDINDMNVTYDAANRIITIKSTGGGTGNSPARLMPDKILDLKYKLRVNNVPTPRTVT
    FNDTLTYKTYSQDFINSPAESHTVSTNPYTIDIIMNKDALQAEVDRRIQQADYTFASL
    DIFNDLKRRAQTILDENRNNVPLNKRVSQADIDSLANQMQHTLIRSVDAENAVNRK
    VDDMEDLVNQNDELTDEEKQAAIQVIEEHKNEIIGNIGDQTTDDGVTRIKDQGIQTL
    SGDTATPVVKPNAKQAIRDKAAKQREIINHTPDATQDEIQDALNQLTTDETDAIDNV
    TNATTNADVETAKNNGINTIGAVAPQVTHKQAARDAINQATATKRQQINSNREATQ
    EEKNAALNELTQATNHALEQINQATTNDDVDTAKGDGLNAINPIAPVTVVKQAARD
    AVSHDAQQHIAEINANPDATQEERQAAIEKVYAAVAVANTNILNANTNADVEQVKT
    NAIQGIQAIEPATKVKTDAKNAIDQSAETQHNAIFNNNDATLEEQQAAQQLLDQAVA
    TAKQNINAADTNQEVAQAKDQGTQNIVVIQPATQVKTDARNAVNEKAREAITNINA
    TPGATREEKQEAINRVNTLKNRALNDIGVTSTTAMVNSIRDDAVNQIGAVQPHVTK
    KQTATGVLTDLATAKKQEINQNTNATTEEKQVALNQVDQDLATAINNINQADTNAE
    VDQAQQLGTKAINAIQPNIVKKPAALAQTNQHYSAKLVEINATPDATDDEKNAAINT
    LNQDRQQAIESIKQANTNAEVDQAATVAENNIDAVQVDVVKKQAARDKITAEVAKR
    IEAVKQTPNATDEEKQAAVNQINQLKDQAFNQINQNQTNDQVDATTNQAINAIDNV
    EAEVVIKPKAIADIEKAVKEKQQQIDNSLDSTDNEKEVALQALAKEKEKALAAIDQA
    QTNSQVNQAATNGVSAIKIIQPETKIKPAAREKINQKANELRAQINQDKEATAEERQ
    AALDKINDLVAKAMTNITNDRTNQQVNDSTNQALDDIALVTPDHIVRAAARDAVKQ
    QYEAKKHEIEQAEHATDEEKQVALNQLANNEKRALQNINQAIANNDVKRVESNGIA
    TLKGVEPHIVVKPEAQEAIKASADNQVESIKDTPHATTDELDEANQQINDTLKQGQ
    QDIDNTTQDAAVNDVRNQTIKAIEQIKPKVRRKRAALDNIDESNNNQLDAIRNTLDT
    TQDERNVAIAALNKIVNAIKNDIAQNKTNAEVDQTEADGNNNIKVILPKVQVKPAAR
    QSVSAKAEAQNALIDQSDLSTEEERLAAKHLVEQALNQAIDQINHADKTAQVNQNS
    IDAQNIISKIKPATTVKATALQQIQNIATNKINLIKANNEATDEEQNAAIVQVEKELIKA
    KQQIAGAVTNADVAYLLHDGKNEIREIEPVINKKATAREQLTTLFNDKKQAIEANVQ
    ATVEERNSILAQLQNIYDTAIGQIDQDRSNAQVDKTATLNLQTIHDLDVHPIKKPDAE
    KTINDDLARVTHLVQNYRKVSDRNKADALKAITALKLQMDEELKTARTNADVDAVL
    KRFNVALGDIEAVITEKENSLLRIDNIAQQTYAKFKAIATPEQLAKVKALIDQYVADG
    NRMVDEDATLNDIKKDTQLIIDEILAIKLPAEVIKASPKVGQPAPKVCTPIKKEDKQEV
    RKVVKELPNTGSEEMDLPLKELALITGAALLARRFRSKKEKES
    DsqA (8325)
    tctaatgaatgtaaagataatacaaggagttattacatgagtaaaagacagaaagcatttcatgacagcttagcaaa (SEQ ID NO:3)
    cgaaaaaacaagagtaagactttataaatctggaaaaaattgggtaaaatccggaattaaagaaatagaaatgttc
    aaaattatggggctaccatttattagtcatagtttagtgagtcaagataatcaaagcattagtaaaaaaatgacgggat
    acggactgaaaactacggcggttattggtggtgcattcacggtaaatatgttgcatgaccagcaagcttttgcggcttct
    gatgcaccattaacttctgaattaaacacacaaagtgaaacagtaggtaatcaaaactcaacgacaatcgaagcat
    caacatcaacagccgattccacaagtgtaacgaaaaatagtagttcggtacaaacatcaaatagtgacacagtctc
    aagtgaaaagtctgaaaaggtcacttcgacaactaatagtacaagcaatcaacaagagaaattgacatctacatc
    agaatcaacatcctcaaagaatactacatcaagttctgatactaaatctgtagcttcaacttcaagtacagaacaacc
    aattaatacatcaacaaatcaaagtactgcatcaaataacacttcacaaagcacaacgccatcttcggtcaacttaa
    acaaaactagcacaacgtcaactagcaccgcaccagtaaaacttcgaactttcagtcgcttagctatgtcaacatttg
    cgtcagcagcgacgacaaccgcagtaactgctaatacaattacagttaataaagataacttaaaacaatatatgac
    aacgtcaggtaatgctacctatgatcaaagtaccggtattgtgacgttaacacaggatgcatacagccaaaaaggtg
    ctattacattaggaacacgtattgactctaataagagttttcatttttctggaaaagtaaatttaggtaacaaatatgaag
    ggcatggaaatggtggagatggtatcggttttgccttttcaccaggtgtattaggtgaaacagggttaaacggtgccgc
    agtaggtattggtggcttaagtaacgcatttggcttcaaattggatacgtatcacaatacatctaaaccaaattcagctg
    caaaggcgaatgctgacccatctaatgtagctggtggaggtgcgtttggtgcatttgtaacaacagatagttatggtgtt
    gcgacaacgtatacatcaagttcaacagctgataatgctgcgaagttaaatgttcaacctacaaataacacgttcca
    agattttgatattaactataatggtgatacaaaggttatgactgtcaaatatgcaggtcaaacatggacacgtaatattt
    cagattggattgcgaaaagtggtacgaccaacttttcattatcaatgacagcctcaacaggtggcgcgacaaatttac
    aacaagtacaatttggaacattcgaatatacagagtctgctgttacacaagtgagatacgttgatgtaacaacaggta
    aagatattattccaccaaaaacatattcaggaaatgttgatcaagtcgtgacaatcgataatcagcaatctgcattga
    ctgctaaaggatataactacacgtccgtcgatagttcatatgcgtcaacttataatgatacaaataaaactgtaaaaat
    gacgaatgctggacaatcagtgacatattattttactgatgtaaaagcaccaactgtaactgtaggcaatcaaaccat
    agaagtgggtaaaacaatgaatcctattgtattgactacaacggataatggtactgggactgtgacaaatacagttac
    aggattaccaagcggattaagttacgatagtgcaacgaattcaatcattgggacaccaacaaaaattggtcaatca
    acagtgacagttgtgtctactgaccaagcaaataacaaatcgacgacaacttttacaataaatgttgtggatacgaca
    gcaccaacagtgacaccaataggagatcaatcatcagaagtgtattcaccaatatccccgattaaaattgctacgca
    agataacagtggaaatgcggtgacgaatacagtgactggattgccatccggactaacatttgatagtacaaataata
    ctattagtggtacaccaacaaacattggtacaagtactatatcaatcgtttctacagatgcgagcggtaacaaaacga
    cgacaacttttaaatatgaagtaacaagaaatagcatgagtgattccgtatcaacatcaggaagtacacaacaatct
    caaagtgtgtcaacaagtaaagctgactcacaaagtgcatcaacgagtacatcaggatcgattgtggtatctacatc
    agctagtacctcgaaatcgacaagtgtaagcctatctgattctgtgagtgcatctaagtcattaagcacatctgaaagt
    aatagtgtatcaagctcaacaagcacaagtttagtgaattcacaaagtgtatcatcaagcatgtcggattcagctagt
    aaatcaacatcattaagcgattctatttcaaactctagcagtactgaaaaatccgaaagtctatcaacaagtacatctg
    attcattgcgtacatcaacatcactcagtgactcattaagtatgagtacatcaggaagcttgtctaagtcacaaagctta
    tcaacgagtatatcagggtcgtctagtacatcagcatcattaagtgacagtacatcgaatgcaattagtacatcaacat
    cattgagcgagtcagctagcacctcggactctatcagtatttcaaatagcatagccaactctcaaagtgcgtcaacaa
    gcaaatcagattcacaaagtacatcaatatcattaagtacaagtgattcaaaatcgatgagtacatcagaatcattga
    gcgattcgacgagcacaagtggttctgtttctggatcactaagcatagcagcatcacaaagtgtctcaacaagtacat
    cagactcgatgagtacttcagagatagtaagtgactctatcagtacaagtgggtcattatctgcatcagacagtaaatc
    aatgtccgtaagtagttcaatgagcacgtctcagtcaggtagtacatcagaatcattaagtgattcacaaagtacatct
    gattctgatagtaagtcattatcacaaagtactagtcaatcaggttcaacaagtacatcaacgtcgacaagtgcttcag
    tacgtacttcggaatcacaaagtacgtctggttcaatgagtgcaagtcaatccgattcaatgagcatatcaacgtcgttt
    agtgattcaacgagtgatagcaaatcagcatcaactgcatcaagtgaatcaatatcacaaagtgcttctacgagcac
    atctggttcggtaagtacttcgacatcgttaagtacaagtaattcagaacgtacatcaacatctatgagtgattccacaa
    gcttaagtacatcagagtctgattcaataagtgaatcaacgtcaacgagcgactctataagtgaagcaatatctgcttc
    agagagcacgtttatatcattaagtgaatcaaatagtactagcgattcagaatcacaaagtgcatctgcctttttaagtg
    aatcattaagtgaaagtacgtctgaatcaacatcagagtcagtgagtagttcgacaagtgagagtacgtcattatcag
    acagtacatcagaatctggtagcacatcaacatcattaagtaattcaacaagtggtagtacgtccatttcaacatcga
    caagtatcagtgaatcaacgtcaacgtttaagagcgagagtgtttcaacatcactgagtatgtcaacgagtacaagtt
    tgtctgactctacaagtttgtcaacatcattaagtgattccacaagtgatagtaagtctgattcattaagtacatcaatgtc
    gacaagtgattcaatcagtacaagtaaatctgattccattagtacatccacatcattaagtggttctacaagtgaaagt
    gaatccgactcaacatcatcaagtgaaagtaaatccgattcaacatcaatgagcataagtatgtctcaatcaacatc
    aggaagtacaagtacgtcaacgagtacaagtttgtctgactcaacgagtacatcattgtcactaagtgcctcaatgaa
    tcaaagcggagtagactcaaactcagcaagccaaagtgcctcaaactcaacaagtacaagcacgagcgaatcc
    gattcacaaagcacatcatcatatacaagtcagtcaacaagccaaagtgaatccacatcgacatcaacgtcactaa
    gcgattcaacaagtatatctaaaagtacgagtcaatcaggttcggtaagcacatcagcgtcattaagtggttcagag
    agtgaatctgattcacaaagtatctcaacaagtgcaagtgagtcaacatcagaaagtgcgtcaacatcactcagtga
    ctcaacaagtacaagtaactcaggatcagcaagtacgtcaacatcgctcagtaactcagcaagcgcaagtgaatc
    cgatttgtcgtcaacatctttaagtgattcaacatctgcgtcaatgcaaagcagtgaatccgattcacaaagcacatca
    gcatcattaagtgattcgctaagtacatcaacttcaaaccgcatgtcgaccattgcaagtttatctacatcggtaagtac
    atcagagtctggctcaacatcagaaagtacaagtgaatccgattcaacatcaacatcattaagcgattcacaaagc
    acatcaagaagtacaagtgcatcaggatcagcaagtacatcaacatcaacaagtgactctcgtagtacatcagctt
    caactagtacttcgatgcgtacaagtactagtgattcacaaagtatgtcgctttcgacaagtacatcaacaagtatgag
    tgattcaacgtcattatctgatagtgttagtgattcaacatcagactcaacaagtgcgagtacatctggttcgatgagtgt
    gtctatatcgttaagtgattcgacaagtacatcaacatcggctagtgaagtaatgagcgcaagcatatctgattcacaa
    agtatgtcagaatctgtaaatgattcagaaagtgtaagtgaatctaattctgaaagtgactctaaatcgatgagtggctc
    aacaagtgtcagtgattctggctcattgagcgtctcaacgtcattaagaaaatcagaaagtgtaagcgagtcaagttc
    attgagttgctcacaatcgatgagcgattcagtaagcacaagcgattcgtcatcattaagtgtatcgacgtcactaaga
    agttcagaaagcgtgagtgaatctgattcattaagtgattcaaaatcaacaagtggttcgacttcaacaagtacatctg
    gttcattgagtacctcaacatcattaagtggttcagaaagcgtaagcgagtctacctcgctaagtgattcaatatcaatg
    agtgattctactagtacaagtgactccgactcattaagtggatcaatatctttaagtggttccacaagtcttagcacttcg
    gattcattaagtgattcaaaatcattgagtagctcgcaaagtatgagtggatcagaatcaacgtcaacaagtgtgagc
    gattcgcagtcaagctcaacaagtaatagtcaatttgactctatgagcatcagtgcatcagaaagcgactcaatgtct
    acaagtgattcgtctagcatcagtggatcaaattcaacgagtacatcactttcaacatctgactcaatgagcggaagc
    gtatcagtttcaacatcgacaagtttaagtgactcaatatcaggttcaacaagtgtaagtgactcgagctcaacaagc
    acatctacatcattaagtgattcaatgtcacaaagccagtcaacaagtacaagtgcatctggttccttaagtacatcga
    tatcaacatcaatgtcaatgagtgctagtacatcgtcatcacaaagcacatcggtgtcgacatcattatcaacatcag
    acagtatcagtgattctacttcaataagtatcagtggttcacaaagtacagtagaatcagaatctacaagtgattcaac
    ttctatcagtgactcagaatcattgagtacatcagattcagactcgacatcgacaagtacatcggactcaacaagtgg
    ttcaacttcaacaagcatatctgaatcattaagtacgtctggttcaggttcaacgagcgtatctgactcaacatcaatga
    gtgaatctaattcatcgagtgtttcaatgtcacaagacaaatccgactcaacatcaattagtgactcagaatcagtgtc
    aacaagcacatcaacgtcattgagcacatccgattcgacaagcacatccgaatcactgagtacatctatgtctggttc
    acaaagcatttctgactcaacatcaacaagtatgtccggctcaacaagtacatctgaatctaactcaatgcatccgtc
    agactcaatgagtatgcatcatactcacagcacgagcacatctcgcttatcaagtgaagcaacaacgagcacgagt
    gaatctcagtctacattaagtgcaacatctgaagtgactaaacataatggcacaccagcacaaagtgaaaaaaga
    ttgccagatacaggtgactcaataaaacaaaatggattactaggtggcgttatgacattattagttggtttaggtttaatg
    aagagaaagaaaaagaaagatgaaaatgatcaagatgattctcaagcataa
    DsqA (8325)
    SNECKDNTRSYYMSKRQKAFHDSLANEKTRVRLYKSGKNWVKSGIKEIEMFKIMG (SEQ ID NO:4)
    LPFISHSLVSQDNQSISKKMTGYGLKTTAVIGGAFTVNMLHDQQAFAASDAPLTSE
    LNTQSETVGNQNSTTIEASTSTADSTSVTKNSSSVQTSNSDTVSSEKSEKVTSTTN
    STSNQQEKLTSTSESTSSKNTTSSSDTKSVASTSSTEQPINTSTNQSTASNNTSQS
    TTPSSVNLNKTSTTSTSTAPVKLRTFSRLAMSTFASAATTTAVTANTITVNKDNLKQ
    YMTTSGNATYDQSTGIVTLTQDAYSQKGAITLGTRIDSNKSFHFSGKVNLGNKYEG
    HGNGGDGIGFAFSPGVLGETGLNGAAVGIGGLSNAFGFKLDTYHNTSKPNSAAKA
    NADPSNVAGGGAFGAFVTTDSYGVATTYTSSSTADNAAKLNVQPTNNTFQDFDIN
    YNGDTKVMTVKYAGQTWTRNISDWIAKSGTTNFSLSMTASTGGATNLQQVQFGT
    FEYTESAVTQVRYVDVTTGKDIIPPKTYSGNVDQVVTIDNQQSALTAKGYNYTSVD
    SSYASTYNDTNKTVKMTNAGQSVTYYFTDVKAPTVTVGNQTIEVGKTMNPIVLTTT
    DNGTGTVNTVTGLPSGLSYDSATNSIIGTPTKIGQSTVTVVSTDQANNKSTTTFTI
    NVVDTTAPTVTPIGDQSSEVYSPISPIKIATQDNSGNAVTNTVTGLPSGLTFDSTNN
    TISGTPTNIGTSTISIVSTDASGNKTTTTFKYEVTRNSMSDSVSTSGSTQQSQSVST
    SKADSQSASTSTSGSIVVSTSASTSKSTSVSLSDSVSASKSLSTSESNSVSSSTST
    SLVNSQSVSSSMSDSASKSTSLSDSISNSSSTEKSESLSTSTSDSLRTSTSLSDSL
    SMSTSGSLSKSQSLSTSISGSSSTSASLSDSTSNAISTSTSLSESASTSDSISISNSI
    ANSQSASTSKSDSQSTSISLSTSDSKSMSTSESLSDSTSTSGSVSGSLSIAASQSV
    STSTSDSMSTSEIVSDSISTSGSLSASDSKSMSVSSSMSISQSGSTSESLSDSQST
    SDSDSKSLSQSTSQSGSTSTSTSTSASVRTSESQSTSGSMSASQSDSMSISTSFS
    DSTSDSKSASTASSESISQSASTSTSGSVSTSTSLSTSNSERTSTSMSDSTSLSTS
    ESDSISESTSTSDSISEAISASESTFISLSESNSTSDSESQSASAFLSESLSESTSES
    TSESVSSSTSESTSLSDSTSESGSTSTSLSNSTSGSTSISTSTSISESTSTFKSESV
    STSLSMSTSTSLSDSTSLSTSLSDSTSDSKSDSLSTSMSTSDSISTSKSDSISTSTS
    LSGSTSESESDSTSSSESKSDSTSMSISMSQSTSGSTSTSTSTSLSDSTSTSLSLS
    ASMNQSGVDSNSASQSASNSTSTSTSESDSQSTSSYTSQSTSQSESTSTSTSLS
    DSTSISKSTSQSGSVSTSASLSGSESESDSQSISTSASESTSESASTSLSDSTSTS
    NSGSASTSTSLSNSASASESDLSSTSLSDSTSASMQSSESDSQSTSASLSDSLST
    STSNRMSTIASLSTSVSTSESGSTSESTSESDSTSTSLSDSQSTSRSTSASGSAST
    STSTSDSRSTSASTSTSMRTSTSDSQSMSLSTSTSTSMSDSTSLSDSVSDSTSDS
    TSASTSGSMSVSISLSDSTSTSTSASEVMSASISDSQSMSESVNDSESVSESNSE
    SDSKSMSGSTSVSDSGSLSVSTSLRKSESVSESSSLSCSQSMSDSVSTSDSSSLS
    VSTSLRSSESVSESDSLSDSKSTSGSTSTSTSGSLSTSTSLSGSESVSESTSLSDS
    ISMSDSTSTSDSDSLSGSISLSGSTSLSTSDSLSDSKSLSSSQSMSGSESTSTSVS
    DSQSSSTSNSQFDSMSISASESDSMSTSDSSSISGSNSTSTSLSTSDSMSGSVSV
    STSTSLSDSISGSTSVSDSSSTSTSTSLSDSMSQSQSTSTSASGSLSTSISTSMSM
    SASTSSSQSTSVSTSLSTSDSISDSTSISISGSQSTVESESTSDSTSISDSESLSTSD
    SDSTSTSTSDSTSGSTSTSISESLSTSGSGSTSVSDSTSMSESNSSSVSMSQDKS
    DSTSISDSESVSTSTSTSLSTSDSTSTSESLSTSMSGSQSISDSTSTSMSGSTSTS
    ESNSMHPSDSMSMHHTHSTSTSRLSSEATTSTSESQSTLSATSEVTKHNGTPAQ
    SEKRLPDTGDSIKQNGLLGGVMTLLVGLGLMKRKKKKDENDQDDSQA
    KesK1 (8325)
    ttattatcaattaaatataatcttataggagttgttaacaacatgaacaaacatcacccaaaattaaggtctttctattctat (SEQ ID NO:5)
    tagaaaatcaactctaggcgttgcatcggtcattgtcagtacactatttttaattacttctcaacatcaagcacaagcag
    cagaaaatacaaatacttcagataaaatctcggaaaatcaaaataataatgcaactacaactcagccacctaagg
    atacaaatcaaacacaacctgctacgcaaccagcaaacactgcgaaaaactatcctgcagcggatgaatcactta
    aagatgcaattaaagatcctgcattagaaaataaagaacatgatataggtccaagagaacaagtcaatttccagtta
    ttagataaaaacaatgaaacgcagtactatcactttttcagcatcaaagatccagcagatgtgtattacactaaaaag
    aaagcagaagttgaattagacatcaatactgcttcaacatggaagaagtttgaagtctatgaaaacaatcaaaaatt
    gccagtgagacttgtatcatatagtcctgtaccagaagaccatgcctatattcgattcccagtttcagatggcacacaa
    gaattgaaaattgtttcttcgactcaaattgatgatggagaagaaacaaattatgattatactaaattagtatttgctaaa
    cctatttataacgatccttcacttgtaaaatcagatacaaatgatgcagtagtaacgaatgatcaatcaagttcagtcgc
    aagtaatcaaacaaacacgaatacatctaatcaaaatatatcaacgatcaacaatgctaataatcaaccgcaggc
    aacgaccaatatgagtcaacctgcacaaccaaaatcgtcaacgaatgcagatcaagcgtcaagccaaccagctc
    atgaaacaaattctaatggtaatactaacgataaaacgaatgagtcaagtaatcagtcggatgttaatcaacagtatc
    caccagcagatgaatcactacaagatgcaattaaaaacccggctatcatcgataaagaacatacagctgataattg
    gcgaccaattgattttcaaatgaaaaatgataaaggtgaaagacagttctatcattatgctagtactgttgaaccagca
    actgtcatttttacaaaaacaggaccaataattgaattaggtttaaagacagcttcaacatggaagaaatttgaagttt
    atgaaggtgacaaaaagttaccagtcgaattagtatcatatgattctgataaagattatgcctatattcgtttcccagtat
    ctaatggtacgagagaagttaaaattgtgtcatctattgaatatggtgagaacatccatgaagactatgattatacgcta
    atggtctttgcacagcctattactaataacccagacgactatgtggatgaagaaacatacaatttacaaaaattattag
    ctccgtatcacaaagctaaaacgttagaaagacaagtttatgaattagaaaaattacaagagaaattgccagaa
    aaatataaggcggaatataaaaagaaattagatcaaactagagtagagttagctgatcaagttaaatcagcagtga
    cggaatttgaaaatgttacacctacaaatgatcaattaacagatttacaagaagcgcattttgttgtttttgaaagtgaa
    gaaaatagtgagtcagttatggacggctttgttgaacatccattctatacagcaactttaaatggtcaaaaatatgtagt
    gatgaaaacaaaggatgacagttactggaaagatttaattgtagaaggtaaacgtgtcactactgtttctaaagatcct
    aaaaataattctagaacgctgattttcccatatatacctgacaaagcagtttacaatgcgattgttaaagtcgttgtggc
    aaacattggttatgaaggtcaatatcatgtcagaattataaatcaggatatcaatacaaaagatgatgatacatcaca
    aaataacacgagtgaaccgctaaatgtacaaacaggacaagaaggtaaggttgctgatacagatgtagctgaaa
    atagcagcactgcaacaaatcctaaagatgcgtctgataaagcagatgtgatagaaccagagtctgacgtggttaa
    agatgctgataataatattgataaagatgtgcaacatgatgttgatcatttatccgatatgtcggataataatcacttcga
    taaatatgatttaaaagaaatggatactcaaattgccaaagatactgatagaaatgtggataaagatgccgataat
    agcgttggtatgtcatctaatgtcgatactgataaagactctaataaaaataaagacaaagtcatacagctgaatcat
    attgccgataaaaataatcatactggaaaagcagcaaagcttgacgtagtgaaacaaaattataataatacagaca
    aagttactgacaaaaaaacaactgaacatctgccgagtgatattcataaaactgtagataaaacagtgaaaacaa
    aagaaaaagccggcacaccatcgaaagaaaacaaacttagtcaatctaaaatgctaccaaaaactggagaa
    acaacttcaagccaatcatggtggggcttatatgcgttattaggtatgttagctttattcattcctaaattcagaaaagaat
    ctaaataa
    KesK1 (8325)
    LLSIKYNLIGVVNNMNKHHPKLRSFYSIRKSTLGVASVIVSTLFLITSQHQAQAAENT (SEQ ID NO:6)
    NTSDKISENQNNNATTTQPPKDTNQTQPATQPANTAKNYPAADESLKDAIKDPALE
    NKEHDIGPREQVNFQLLDKNNETQYYHFFSIKDPADVYYTKKKAEVELDINTASTW
    KKFEVYENNQKLPVRLVSYSPVPEDHAYIRFPVSDGTQELKIVSSTQIDDGEETNY
    DYTKLVFAKPIYNDPSLVKSDTNDAVVTNDQSSSVASNQTNTNTSNQNISTINNAN
    NQPQATTNMSQPAQPKSSTNADQASSQPAHETNSNGNTNDKTNESSNQSDVNQ
    QYPPADESLQDAIKNPAIIDKEHTADNWRPIDFQMKNDKGERQFYHYASTVEPATV
    IFTKTGPIIELGLKTASTWKKFEVYEGDKKLPVELVSYDSDKDYAYIRFPVSNGTRE
    VKIVSSIEYGENIHEDYDYTLMVFAQPITNNPDDYVDEETYNLQKLLAPYHKAKTLE
    RQVYELEKLQEKLPEKYKAEYKKKLDQTRVELADQVKSAVTEFENVTPTNDQLTD
    LQEAHFWFESEENSESVMDGFVEHPFYTATLNGQKYVVMKTKDDSYWKDLIVEG
    KRVTTVSKDPKNNSRTLIFPYIPDKAVYNAIVKVVVANIGYEGQYHVRIINQDINTKD
    DDTSQNNTSEPLNVQTGQEGKVADTDVAENSSTATNPKDASDKADVIEPESDVVK
    DADNNIDKDVQHDVDHLSDMSDNNHFDKYDLKEMDTQIAKDTDRNVDKDADNSV
    GMSSNVDTDKDSNKNKDKVIQLNHIADKNNHTGKAAKLDVVKQNYNNTDKVTDKK
    TTEHLPSDIHKTVDKTVKTKEKAGTPSKENKLSQSKMLPKTGETTSSQSWWGLYA
    LLGMLALFIPKFRKESK
    KrkN2 (8325)
    gaggaaaacaacatgacaaaacattatttaaacagtaagtatcaatcagaacaacgttca (SEQ ID NO:7)
    tcagctatgaaaaagattacaatgggtacagcatctatcattttaggttcccttgtatac
    ataggcgcagacagccaacaagtcaatgcggcaacagaagctacgaacgcaactaataat
    caaagcacacaagtttctcaagcaacatcacaaccaattaatttccaagtgcaaaaagat
    ggctcttcagagaagtcacacatggatgactatatgcaacaccctggtaaagtaattaaa
    caaaataataaatattatttccaaaccgtgttaaacaatgcatcattctggaaagaatac
    aaattttacaatgcaaacaatcaagaattagcaacaactgttgttaacgataataaaaaa
    gcggatactagaacaatcaatgttgcagttgaacctggatataagagcttaactactaaa
    gtacatattgtcgtgccacaaattaattacaatcatagatatactacgcatttggaattt
    gaaaaagcaattcctacattagctgacgcagcaaaaccaaacaatgttaaaccggttcaa
    ccaaaaccagctcaacctaaaacacctactgagcaaactaaaccagttcaacctaaagtt
    gaaaaagttaaacctactgtaactacaacaagcaaagttgaagacaatcactctactaaa
    gttgtaagtactgacacaacaaaagatcaaactaaaacacaaactgctcatacagttaaa
    acagcacaaactgctcaagaacaaaataaagttcaaacacctgttaaagatgttgcaaca
    gcgaaatctgaaagcaacaatcaagctgtaagtgataataaatcacaacaaactaacaaa
    gttacaaaacataacgaaacgcctaaacaagcatctaaagctaaagaattaccaaaaact
    ggtttaacttcagttgataactttattagcacagttgccttcgcaacacttgccctttta
    ggttcattatctttattacttttcaaaagaaaagaatctaaataa
    KrkN2 (8325)
    EENNMTKHYLNSKYQSEQRSSAMKKITMGTASIILGSLVYIGADSQQVNAATEATN (SEQ ID NO:8)
    ATNNQSTQVSQATSQPINFQVQKDGSSEKSHMDDYMQHPGKVIKQNNKYYFQTV
    LNNASFWKEYKFYNANNQELATTVVNDNKKADTRTINVAVEPGYKSLTTKVHIVVP
    QINYNHRYTTHLEFEKAIPTLADAAKPNNVKPVQPKPAQPKTPTEQTKPVQPKVEK
    VKPTVTTTSKVEDNHSTKVVSTDTTKDQTKTQTAHTVKTAQTAQEQNKVQTPVKD
    VATAKSESNNQAVSDNKSQQTNKVTKHNETPKQASKAKELPKTGLTSVDNFISTV
    AFATLALLGSLSLLLFKRKESK
    KrkN (8325)
    tatacaattaggagttgtttctacaacatgaacaaacagcaaaaagaatttaaatcattttattcaattagaaagtcatc (SEQ ID NO:9)
    actaggcgttgcatctgtagcaattagtacacttttattattaatgtcaaatggcgaagcacaagcagcagctgaaga
    aacaggtggtacaaatacagaagcacaaccaaaaactgaagcagttgcaagtccaacaacaacatctgaaaaa
    gctccagaaactaaaccagtagctaatgctgtctcagtatctaataaagaagttgaggcccctacttctgaaacaaa
    agaagctaaagaagttaaagaagttaaagcccctaaggaaacaaaagaagttaaaccagcagcaaaagccac
    taacaatacatatcctattttgaatcaggaacttagagaagcgattaaaaaccctgcaataaaagacaaagatcata
    gcgcaccaaactctcgtccaattgattttgaaatgaaaaagaaagatggaactcaacagttttatcattatgcaagttc
    tgttaaacctgctagagttattttcactgattcaaaaccagaaattgaattaggattacaatcaggtcaattttggagaaa
    atttgaagtttatgaaggtgacaaaaagttgccaattaaattagtatcatacgatactgttaaagattatgcttacattcg
    cttctctgtatcaaacggaacaaaagctgttaaaattgttagttcaacacacttcaataacaaagaagaaaaatacg
    attacacattaatggaattcgcacaaccaatttataacagtgcagataaattcaaaactgaagaagattataaagctg
    aaaaattattagcgccatataaaaaagcgaaaacactagaaagacaagtttatgaattaaataaaattcaagataa
    acttcctgaaaaattaaaggctgagtacaagaagaaattagaggatacaaagaaagctttagatgagcaagtgaa
    atcagctattactgaattccaaaatgtacaaccaacaaatgaaaaaatgactgatttacaagatacaaaatatgttgtt
    tatgaaagtgttgagaataacgaatctatgatggatacttttgttaaacaccctattaaaacaggtatgcttaacggcaa
    aaaatatatggtcatggaaactactaatgacgattactggaaagatttcatggttgaaggtcaacgtgttagaactata
    agcaaagatgctaaaaataatactagaacaattattttcccatatgttgaaggtaaaactctatatgatgctatcgttaa
    agttcacgtaaaaacgattgattatgatggacaataccatgtcagaatcgttgataaagaagcatttacaaaagcca
    ataccgataaatctaacaaaaaagaacaacaagataactcagctaagaaggaagctactccagctacgcctagc
    aaaccaacaccatcacctgttgaaaaagaatcacaaaaacaagacagccaaaaagatgacaataaacaattac
    caagtgttgaaaaagaaaatgacgcatctagtgagtcaggtaaagacaaaacgcctgctacaaaaccaactaaa
    ggtgaagtagaatcaagtagtacaactccaactaaggtagtatctacgactcaaaatgttgcaaaaccaacaactg
    cttcatcaaaaacaacaaaagatgttgttcaaacttcagcaggttctagcgaagcaaaagatagtgctccattacaa
    aaagcaaacattaaaaacacaaatgatggacacactcaaagccaaaacaataaaaatacacaagaaaataaa
    gcaaaatcattaccacaaactggtgaagaatcaaataaagatatgacattaccattaatggcattattagctttaagta
    gcatcgttgcattcgtattacctagaaaacgtaaaaactaa
    KrkN (8325)
    YTIRSCFYNMNKQQKEFKSFYSIRKSSLGVASVAISTLLLLMSNGEAQAAAEETGG (SEQ ID NO:10)
    TNTEAQPKTEAVASPTTTSEKAPETKPVANAVSVSNKEVEAPTSETKEAKEVKEV
    KAPKETKEVKPAAKATNNTYPILNQELREAIKNPAIKDKDHSAPNSRPIDFEMKKKD
    GTQQFYHYASSVKPARVIFTDSKPEIELGLQSGQFWRKFEVYEGDKKLPIKLVSYD
    TVKDYAYIRFSVSNGTKAVKIVSSTHFNNKEEKYDYTLMEFAQPIYNSADKFKTEED
    YKAEKLLAPYKKAKTLERQVYELNKIQDKLPEKLKAEYKKKLEDTKKALDEQVKSAI
    TEFQNVQPTNEKMTDLQDTKYVVYESVENNESMMDTFVKHPIKTGMLNGKKYMV
    METTNDDYWKDFMVEGQRVRTISKDAKNNTRTIIFPYVEGKTLYDAIVKVHVKTIDY
    DGQYHVRIVDKEAFTKANTDKSNKKEQQDNSAKKEATPATPSKPTPSPVEKESQK
    QDSQKDDNKQLPSVEKENDASSESGKDKTPATKPTKGEVESSSTTPTKVVSTTQ
    NVAKPTTASSKTTKDVVQTSAGSSEAKDSAPLQKANIKNTNDGHTQSQNNKNTQE
    NKAKSLPQTGEESNKDMTLPLMALLALSSIVAFVLPRKRKN
    RkaS (COL)
    tttataaataatttacataaaatcaatcattttaatataaggattatgataatatattggtgtatgacagttaatggaggga (SEQ ID NO:11)
    acgaaatgaaagctttattacttaaaacaagtgtatggctcgttttgctttttagtgtaatgggattatggcaagtctcgaa
    cgcggctgagcagcatacaccaatgaaagcacatgcagtaacaacgatagacaaagcaacaacagataagca
    acaagtaccgccaacaaaggaagcggctcatcattctggcaaagaagcggcaaccaacgtatcagcatcagcg
    cagggaacagctgatgatacaaacagcaaagtaacatccaacgcaccatctaacaaaccatctacagtagtttca
    acaaaagtaaacgaaacacgcgacgtagatacacaacaagcctcaacacaaaaaccaactcacacagcaac
    gttcaaattatcaaatgctaaaacagcatcactttcaccacgaatgtttgctgctaatgcaccacaaacaacaacaca
    taaaatattacatacaaatgatatccatggccgactagccgaagaaaaagggcgtgtcatcggtatggctaaattaa
    aaacagtaaaagaacaagaaaagcctgatttaatgttagacgcaggagacgccttccaaggtttaccactttcaaa
    ccagtctaaaggtgaagaaatggctaaagcaatgaatgcagtaggttatgatgctatggcagtcggtaaccatgaat
    ttgactttggatacgatcagttgaaaaagttagagggtatgttagacttcccgatgctaagtactaacgtttataaagatg
    gaaaacgcgcgtttaagccttcaacgattgtaacaaaaaatggtattcgttatggaattattggtgtaacgacaccag
    aaacaaagacgaaaacaagacctgaaggcattaaaggcgttgaatttagagatccattacaaagtgtgacagcg
    gaaatgatgcgtatttataaagacgtagatacatttgttgttatatcacatttaggaattgatccttcaacacaagaaaca
    tggcgtggtgattacttagtgaaacaattaagtcaaaatccacaattgaagaaacgtattacagttattgatggtcattc
    acatacagtacttcaaaatggtcaaatttataacaatgatgcattggcacaaacaggtacagcacttgcgaatatcgg
    taagattacatttaattatcgcaatggagaggtatcgaatattaaaccgtcattgattaatgttaaagacgttgaaaatgt
    aacaccgaacaaagcattagctgaacaaattaatcaagctgatcaaacatttagagcacaaactgcagaggtaat
    tattccaaacaataccattgatttcaaaggagaaagagatgacgttagaacgcgtgaaacaaatttaggaaacgcg
    attgcagatgctatggaagcgtatggcgttaagaatttctctaaaaagactgactttgccgtgacaaatggtggaggta
    ttcgtgcctctatcgcaaaaggtaaggtgacacgctatgatttaatctcagtattaccatttggaaatacgattgcgcaa
    attgatgtaaaaggttcagacgtctggacggctttcgaacatagtttaggcgcaccaacaacacaaaaggacggta
    agacagtgttaacagcgaatggcggtttactacatatctctgattcaatccgtgtttactatgatataaataaaccgtctg
    gcaaacgaattaatgctattcaaattttaaataaagagacaggtaagtttgaaaatattgatttaaaacgtgtatatcac
    gtaacgatgaatgacttcacagcatcaggtggcgacggatatagtatgttcggtggtcctagagaagaaggtatttca
    ttagatcaagtactagcaagttatttaaaaacagctaacttagctaagtatgatacgacagaaccacaacgtatgttat
    taggtaaaccagcagtaagtgaacaaccagctaaaggacaacaaggtagcaaaggtagtaagtctggtaaagat
    acacaaccaattggtgacgacaaagtgatggatccagcgaaaaaaccagctccaggtaaagttgtattgttgctag
    cgcatagaggaactgttagtagcggtacagaaggttctggtcgcacaatagaaggagctactgtatcaagcaaga
    gtgggaaacaattggctagaatgtcagtgcctaaaggtagcgcgcatgagaaacagttaccaaaaactggaacta
    atcaaagttcaagcccagaagcgatgtttgtattattagcaggtataggtttaatcgcgactgtacgacgtagaaaag
    ctagctaa
    RkaS (COL)
    FINNLHKINHFNIRIMIIYWCMTVNGGNEMKALLLKTSVWLVLLFSVMGLWQVSNAA (SEQ ID NO:12)
    EQHTPMKAHAVTTIDKATTDKQQVPPTKEAAHHSGKEAATNVSASAQGTADDTN
    SKVTSNAPSNKPSTVVSTKVNETRDVDTQQASTQKPTHTATFKLSNAKTASLSPR
    MFAANAPQTTTHKILHTNDIHGRLAEEKGRVIGMAKLKTVKEQEKPDLMLDAGDAF
    QGLPLSNQSKGEEMAKAMNAVGYDAMAVGNHEFDFGYDQLKKLEGMLDFPMLS
    TNVYKDGKRAFKPSTIVTKNGIRYGIIGVTTPETKTKTRPEGIKGVEFRDPLQSVTA
    EMMRIYKDVDTFVVISHLGIDPSTQETWRGDYLVKQLSQNPQLKKRITVIDGHSHT
    VLQNGQIYNNDALAQTGTALANIGKITFNYRNGEVSNIKPSLINVKDVENVTPNKAL
    AEQINQADQTFRAQTAEVIIPNNTIDFKGERDDVRTRETNLGNAIADAMEAYGVKN
    FSKKTDFAVTNGGGIRASIAKGKVTRYDLISVLPFGNTIAQIDVKGSDVWTAFEHSL
    GAPTTQKDGKTVLTANGGLLHISDSIRVYYDINKPSGKRINAIQILNKETGKFENIDL
    KRVYHVTMNDFTASGGDGYSMFGGPREEGISLDQVLASYLKTANLAKYDTTEPQR
    MLLGKPAVSEQPAKGQQGSKGSKSGKDTQPIGDDKVMDPAKKPAPGKVVLLLAH
    RGTVSSGTEGSGRTIEGATVSSKSGKQLARMSVPKGSAHEKQLPKTGTNQSSSP
    EAMFVLLAGIGLIATVRRRKAS
    RrkN (8325)
    agtggaaaatatggaaaaaggagtatgcaaatgagagataagaaaggaccggtaaataaaagagtagattttct (SEQ ID NO:13)
    atcaaataaattgaataaatattcaataagaaaatttacagttggaacagcatctattttaattggctcactaatgtatttg
    ggaactcaacaagaggcagaagcagctgaaaacaatattgagaatccaactacattaaaagataatgtccaatc
    aaaagaagtgaagattgaagaagtaacaaacaaagacactgcaccacagggtgtagaagctaaatctgaagta
    acttcaaacaaagacacaatcgaacatgaaccatcagtaaaagctgaagatatatcaaaaaaggaggatacac
    caaaagaagtagctgatgttgctgaagttcagccgaaatcgtcagtcactcataacgcagagacacctaaggttag
    aaaagctcgttctgttgatgaaggctcttttgatattacaagagattctaaaaatgtagttgaatctaccccaattacaatt
    caaggtaaagaacattttgaaggttacggaagtgttgatatacaaaaaaaaccaacagatttaggggtatcagagg
    taaccaggtttaatgttggtaatgaaagtaatggtttgataggagctttacaattaaaaaataaaatagattttagtaag
    gatttcaattttaaagttagagtggcaaataaccatcaatcaaataccacaggtgctgatggttgggggttcttatttagt
    aaaggaaatgcagaagaatatttaactaatggtggaatccttggggataaaggtctggtaaattcaggcggatttaa
    aattgatactggatacatttatacaagttccatggacaaaactgaaaagcaagctggacaaggttatagaggatacg
    gagcttttgtgaaaaatgacagttctggtaattcacaaatggttggagaaaatattgataaatcaaaaactaattttttaa
    actatgcggacaattcaactaatacatcagatggaaagtttcatgggcaacgtttaaatgatgtcatcttaacttatgttg
    cttcaactggtaaaatgagagcagaatatgctggtaaaacttgggagacttcaataacagatttaggtttatctaaaaa
    tcaggcatataatttcttaattacatctagtcaaagatggggccttaatcaagggataaatgcaaatggctggatgaga
    actgacttgaaaggttcagagtttacttttacaccagaagcgccaaaaacaataacagaattagaaaaaaaagttg
    aagagattccattcaagaaagaacgtaaatttaatccggatttagcaccagggacagaaaaagtaacaagagaa
    ggacaaaaaggtgagaagacaataacgacaccaacactaaaaaatccattaactggagtaattattagtaaaggt
    gaaccaaaagaagagattacaaaagatccgattaatgaattaacagaatacggacctgaaacaatagcgccag
    gtcatcgagacgaatttgatccgaagttaccaacaggagagaaagaggaagttccaggtaaaccaggaattaag
    aatccagaaacaggagacgtagttagaccgccggtcgatagcgtaacaaaatatggacctgtaaaaggagactc
    gattgtagaaaaagaagagattccattcgagaaagaacgtaaatttaatcctgatttagcaccagggacagaaaaa
    gtaacaagagaaggacaaaaaggtgagaagacaataacgacgccaacactaaaaaatccattaactggagaa
    attattagtaaaggtgaatcgaaagaagaaatcacaaaagatccgattaatgaattaacagaatacggaccagaa
    acgataacaccaggtcatcgagacgaatttgatccgaagttaccaacaggagagaaagaggaagttccaggtaa
    accaggaattaagaatccagaaacaggagatgtagttagaccaccggtcgatagcgtaacaaaatatggacctgt
    aaaaggagactcgattgtagaaaaagaagagattccattcgagaaagaacgtaaatttaatcctgatttagcacca
    gggacagaaaaagtaacaagagaaggacaaaaaggtgagaagacaataacgacaccaacactaaaaaatc
    cattaactggagtaattattagtaaaggtgaaccaaaagaagaaatcacaaaagatccgattaatgaattaacaga
    atacggaccagaaacgataacaccaggtcatcgagacgaatttgatccgaagttaccaacaggagagaaagaa
    gaagttccaggtaaaccaggaattaagaatccagaaacaggagacgtagttagaccaccggtcgatagcgtaac
    aaaatatggacctgtaaaaggagactcgattgtagaaaaagaagagattccattcaagaaagaacgtaaatttaat
    ccggatttagcaccagggacagaaaaagtaacaagagaaggacaaaaaggtgagaagacaataacgacgcc
    aacactaaaaaatccattaactggagaaattattagtaaaggtgaatcgaaagaagaaatcacaaaagatccgat
    taatgaattaacagaatacggaccagaaacgataacaccaggtcatcgagacgaatttgatccgaagttaccaac
    aggagagaaagaggaagttccaggtaaaccaggaattaagaatccagaaacaggagatgtagttagaccaccg
    gtcgatagcgtaacaaaatatggacctgtaaaaggagactcgattgtagaaaaagaagagattccattcgagaaa
    gaacgtaaatttaatcctgatttagcaccagggacagaaaaagtaacaagagaaggacaaaaaggtgagaaga
    caataacgacgccaacactaaaaaatccattaactggagaaattattagtaaaggtgaatcgaaagaagaaatca
    caaaagatccgattaatgaattaacagaatacggaccagaaacgataacaccaggtcatcgagacgaatttgatc
    cgaagttaccaacaggagagaaagaggaagttccaggtaaaccaggaattaagaatccagaaacaggagacg
    tagttagaccaccggtcgatagcgtaacaaaatatggacctgtaaaaggagactcgattgtagaaaaagaagaaa
    ttccattcaagaaagaacgtaaatttaatcctgatttagcaccagggacagaaaaagtaacaagagaaggacaaa
    aaggtgagaagacaataacgacgccaacactaaaaaatccattaactggagaaattattagtaaaggtgaatcga
    aagaagaaatcacaaaagatccgattaatgaattaacagaatacggaccagaaacgataacaccaggtcatcg
    agacgaatttgatccgaagttaccaacaggagagaaagaggaagttccaggtaaaccaggaattaagaatccag
    aaacaggagatgtagttagaccaccggtcgatagcgtaacaaaatatggacctgtaaaaggagactcgattgtag
    aaaaagaagaaattccattcgagaaagaacgtaaatttaatcctgatttagcaccagggacagaaaaagtaacaa
    gagaaggacaaaaaggtgagaagacaataacgacgccaacactaaaaaatccattaactggagaaattattagt
    aaaggtgaatcgaaagaagaaatcacaaaagatccgattaatgaattaacagaatacggaccagaaacgataa
    caccaggtcatcgagacgaatttgatccgaagttaccaacaggagagaaagaggaagttccaggtaaaccagga
    attaagaatccagaaacaggagatgtagttagaccaccggtcgatagcgtaacaaaatatggacctgtaaaagga
    gactcgattgtagaaaaagaagaaattccattcgagaaagaacgtaaatttaatcctgatttagcaccagggacag
    aaaaagtaacaagagaaggacaaaaaggtgagaagacaataacgacgccaacactaaaaaatccattaactg
    gagaaattattagtaaaggtgaatcgaaagaagaaatcacaaaagatccagttaatgaattaacagaattcggtgg
    cgagaaaataccgcaaggtcataaagatatctttgatccaaacttaccaacagatcaaacggaaaaagtaccagg
    taaaccaggaatcaagaatccagacacaggaaaagtgatcgaagagccagtggatgatgtgattaaacacgga
    ccaaaaacgggtacaccagaaacaaaaacagtagagataccgtttgaaacaaaacgtgagtttaatccaaaatt
    acaacctggtgaagagcgagtgaaacaagaaggacaaccaggaagtaagacaatcacaacaccaatcacagt
    gaacccattaacaggtgaaaaagttggcgagggtcaaccaacagaagagatcacaaaacaaccagtagataa
    gattgtagagttcggtggagagaaaccaaaagatccaaaaggacctgaaaacccagagaagccgagcagacc
    aactcatccaagtggcccagtaaatcctaacaatccaggattatcgaaagacagagcaaaaccaaatggcccagt
    tcattcaatggataaaaatgataaagttaaaaaatctaaaattgctaaagaatcagtagctaatcaagagaaaaaa
    cgagcagaattaccaaaaacaggtttagaaagcacgcaaaaaggtttgatctttagtagtataattggaattgctgga
    ttaatgttattggctcgtagaagaaagaattaa
    RrkN (8325)
    SGKYGKRSMQMRDKKGPVNKRVDFLSNKLNKYSIRKFTVGTASILIGSLMYLGTQ (SEQ ID NO:14)
    QEAEAAENNIENPTTLKDNVQSKEVKIEEVTNKDTAPQGVEAKSEVTSNKDTIEHE
    PSVKAEDISKKEDTPKEVADVAEVQPKSSVTHNAETPKVRKARSVDEGSFDITRDS
    KNVVESTPITIQGKEHFEGYGSVDIQKKPTDLGVSEVTRFNVGNESNGLIGALQLK
    NKIDFSKDFNFKVRVANNHQSNTTGADGWGFLFSKGNAEEYLTNGGILGDKGLVN
    SGGFKIDTGYIYTSSMDKTEKQAGQGYRGYGAFVKNDSSGNSQMVGENIDKSKT
    NFLNYADNSTNTSDGKFHGQRLNDVILTYVASTGKMRAEYAGKTWETSITDLGLS
    KNQAYNFLITSSQRWGLNQGINANGWMRTDLKGSEFTFTPEAPKTITELEKKVEEI
    PFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGVIISKGEPKEEITKDPI
    NELTEYGPETIAPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKY
    GPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEII
    SKGESKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETG
    DVVRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEK
    TITTPTLKNPLTGVIISKGEPKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKE
    EVPGKPGIKNPETGDVVRPPVDSTKYGPVKGDSIVEKEEIPFKKERKFNPDLAPG
    TEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPETITPGH
    RDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIP
    FEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPIN
    ELTEYGPETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYG
    PVKGDSIVEKEEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIIS
    KGESKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGD
    VVRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTI
    TTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEE
    VPGKPGIKNPETGDWRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGT
    EKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPVNELTEFGGEKIPQGH
    KDIFDPNLPTDQTEKVPGKPGIKNPDTGKVIEEPVDDVIKHGPKTGTPETKTVEIPF
    ETKREFNPKLQPGEERVKQEGQPGSKTITTPITVNPLTGEKVGEGQPTEEITKQPV
    DKIVEFGGEKPKDPKGPENPEKPSRPTHPSGPVNPNNPGLSKDRAKPNGPVHSM
    DKNDKVKKSKIAKESVANQEKKRAELPKTGLESTQKGLIFSSIIGIAGLMLLARRRK
    N
    KnkA (8325)
    ggaaggagtatgttgatggctaaatatcgagggaaaccgtttcaattatatgtaaagttatcgtgttcgacaatgatggc (SEQ ID NO:15)
    gacaagtatcattttaacgaatatcttgccgtacgatgcccaagctgcatctgaaaaggatactgaaattacaaaaga
    gatattatctaagcaagatttattagacaaagttgacaaggcaattcgtcaaattgagcaattaaaacagttatcggctt
    catctaaagaacattataaagcacaactaaatgaagcgaaaacagcatcgcaaatagatgaaatcataaaacga
    gctaatgagttggatagcaaagacaataaaagttctcacactgaaatgaacggtcaaagtgatatagacagtaaatt
    agatcaattgcttaaagatttaaatgaggtttcttcaaatgttgataggggtcaacaaagtggcgaggacgatcttaat
    gcaatgaaaaatgatatgtcacaaacggctacaacaaaacatggagaaaaagatgataaaaatgatgaagca
    atggtaaataaggcgttagaagacctagaccatttgaatcagcaaatacacaaatcgaaagatgcatcgaaagat
    acatcggaagatccagcagtgtctacaacagataataatcatgaagtagctaaaacgccaaataatgatggttctg
    gacatgttgtgttaaataaattcctttcaaatgaagagaatcaaagccatagtaatcgactcactgataaattacaagg
    aagcgataaaattaatcatgctatgattgaaaaattagctaaaagtaatgcctcaacgcaacattacacatatcataa
    actgaatacgttacaatctttagatcaacgtattgcaaatacgcaacttcctaaaaatcaaaaatcagacttaatgagc
    gaagtaaataagacgaaagagcgtataaaaagtcaacgaaatattattttggaagaacttgcacgtactgatgata
    aaaagtatgctacacaaagcattttagaaagtatatttaataaagacgaggcagttaaaattctaaaagatatacgt
    gttgatggtaaaacagatcaacaaattgcagatcaaattactcgtcatattgatcaattatctctgacaacgagtgatg
    atttattaacgtcattgattgatcaatcacaagataagtcgctattgatttctcaaattttacaaacgaaattaggaaaa
    ctgaagcagataaattggctaaagattggacgaataaaggattatcaaatcgccaaatcgttgaccaattgaagaa
    acattttgcatcaactggcgacacgtcttcagatgatatattaaaagcaattttgaataatgccaaagataaaaaaca
    agcaattgaaacgattttagcaacacgtatagaaagacaaaaggcaaaattactggcagatttaattactaaaata
    gaaacagatcaaaataaaatttttaatttagttaaatcggcattgaatggtaaagcggatgatttattgaatttacaaaa
    gagactcaatcaaacgaaaaaagatatagattatattttatcaccaatagtaaatcgtccaagtttactagatcgattg
    aataaaaatgggaaaacgacagatttaaataagttagcaaatttaatgaatcaaggatcagatttattagacagtatt
    ccagatatacccacaccaaagccagaaaagacgttaacacttggtaaaggtaatggattgttaagtggattattaaa
    tgctgatggtaatgtatctttgcctaaagcgggggaaacgataaaagaacattggttgccgatatctgtaattgttggtg
    caatgggtgtactaatgatttggttatcacgacgcaataagttgaaaaataaagcataa
    KnkA (8325)
    GRSMLMAKYRGKPFQLYVKLSCSTMMATSIILTNILPYDAQAASEKDTEITKEILSK (SEQ ID NO:16)
    QDLLDKVDKAIRQIEQLKQLSASSKEHYKAQLNEAKTASQIDEIIKRANELDSKDNK
    SSHTEMNGQSDIDSKLDQLLKDLNEVSSNVDRGQQSGEDDLNAMKNDMSQTATT
    KHGEKDDKNDEAMVNKALEDLDHLNQQIHKSKDASKDTSEDPAVSTTDNNHEVA
    KTPNNDGSGHVVLNKFLSNEENQSHSNRLTDKLQGSDKINHAMIEKLAKSNASTQ
    HYTYHKLNTLQSLDQRIANTQLPKNQKSDLMSEVNKTKERIKSQRNIILEELARTDD
    KKYATQSILESIFNKDEAVKILKDIRVDGKTDQQIADQITRHIDQLSLTTSDDLLTSLID
    QSQDKSLLISQILQTKLGKAEADKLAKDWTNKGLSNRQIVDQLKKHFASTGDTSSD
    DILKAILNNAKDKKQAIETILATRIERQKAKLLADLITKIETDQNKIFNLVKSALNGKAD
    DLLNLQKRLNQTKKDIDYILSPIVNRPSLLDRLNKNGKTTDLNKLANLMNQGSDLLD
    SIPDIPTPKPEKTLTLGKGNGLLSGLLNADGNVSLPKAGETIKEHWLPISVIVGAMG
    VLMIWLSRRNKLKNKA

    Primary Structure Analysis:
  • A bioinformatic approach was used for primary structure and function prediction (FIG. 1). Proteins RrkN and DsqA possessed a similar structural organization to previously described MSCRAMMs. RrkN is similar in structure to the Pls/Aap proteins of S. aureus and S. epidermidis, respectively. It contains a 200-residue domain at its N-terminus showing 40% identity to Pls and Aap. The C-terminus of the protein is predominantly composed of a 128 residue repeat domain, which varies in the numbers of repeats from strain to strain. These repeats are also present in Pls and Aap. A putative sar homolog and fnbpA and fnbpB lie directly upstream from RrkN on the genome.
  • DsqA is similar in structural organization to the Sdr family of proteins. It contains a typical A domain followed by a TYYFTDVK motif which is similar to a conserved TYTFTVYVD motif found in all of the Sdr proteins. The function of this motif has yet to be determined. Two 88 residue repeat domains reside in the centre of the protein followed by a C-terminal SX-repeat motif similar to the SD-repeat motif found in the Sdr proteins. The size of this repeat varies from strain to strain. DsqA neighbors secY and secA on the genome. A DsqA homolog (>90% identical) is also found in S. epidermidis.
  • KnkA contains no repeat domains in its sequence. Secondary structure prediction analysis indicate that this protein is predominantly composed of alpha-helices.
  • RkaS contains no repeat domains in its sequence. BLAST analysis indicates that it is similar to a 5′ nucleotidase UDP-sugar hydrolase. The gene encoding RkaS lies directly upstream from orfX, the insertion site of the mec element.
  • KesK contains two 140 residue repeat domains at the N-terminus of the protein which are 38% identical. Hydropathy plot analysis (Kyte and Doolittle, 1982) indicates that there is a large hydrophilic domain in the center of the protein (residue 500-560).
  • EkeS contains two 300 residue repeat domains in the center of the protein which are 38% identical. Blast analysis indicates that the N-terminus of the protein (residues 1-1268, bearing both repeats) is 49% identical to FmtB, an LPXTG protein with 17 tandem repeats. FmtB is proposed to be involved indirectly in methicillin resistance as inactivation of fmtB abolishes methicillin resistance. This appears to be due to affecting cell wall composition as methicillin sensitivity can be relieved by increasing the production of the cell wall precursor glucosamine-1-phosphate (Komatsuzawa et al., 2000).
  • KrkN and KrkN2 neighbor each other on the genome.
  • Expression Analysis:
  • Due to lack of sequence homology with protein databases, a putative function for each of these proteins could not be predicted and hence a molecular approach was taken. Unique regions of four of the offs were expressed in E. coli as recombinant his-tagged fusion proteins using the Qiagen pQE-30 expression system. FIG. 2. represents a Coomassie stained SDS-PAGE gel of the purified N-terminal his-tag fusion proteins. The recombinant proteins RrkN1, DsqA2, KesK1 and KnkA were used to generate antibodies in rabbits. Western blotting analysis of S. aureus cell wall extracts revealed that KesK, KnkA and DsqA are expressed and cell wall-associated (FIG. 3). Strain eMRSA-16 represents a knkA-negative strain since it lacks the knkA gene. An immunoreactive band of 65 kDa reacts with the cell wall fraction from both exponential and stationary phase cells of strain 8325-4 (FIG. 3, B). The absence of this band in strain eMRSA-16 suggests that it represents the gene product of knkA.
  • Western immunoblotting of the cell wall fraction of strain 8325-4 using anti-KesK antibodies identified a 150 kDa immunoreactive band in both exponential and stationary phase cultures. A similar sized immunoreactive protein released from the cell wall fraction of Lactococcus lactis expressing full length KesK on an expression plasmid (pKS80) suggests that the 150 kDa band represents the kesK gene product (data not shown). A kesk knockout mutant in S. aureus would be required to confirm the size of the cell wall-released KesK protein.
  • Western immunoblotting of the cell wall fraction of S. aureus strain MSSA and eMRSA-16 using anti-DsqA antibodies identified a 130 kDa immunoreactive band. Expression levels are higher in stationary phase cells.
  • Heterologous Expression in Lactococcus lactis:
  • Heterologous expression of S. aureus surface proteins in Lactococcus lactis (L. lactis) has previously been used as a tool to study protein function (Sinha et al., 2000). In this study this surrogate system will be used to express each of the in silico-predicted MSCRAMMs on the surface of L. lactis to fish for a function. KesK and KnkA have been cloned into L. lactis and shown by dot blotting to be surface expressed (FIG. 4). No cross reaction was observed with the negative control (pKS80 plasmid without an insert) indicating that this is a specific reaction. Cell wall and protoplast fractions of Lactococcus lactis bearing pKS-KnkA and pKS-KesK were generated by digestion of cells with lysozyme and mutanolysin and used in Western blotting studies using anti-KnkA and anti-KesK antibodies, respectively. Unlike what was observed in S. aureus, KnkA was not detected in the cell wall fraction of L. lactis but found to be associated with the protoplast fraction. The anchoring motif of KnkA differs from the consensus LPXTG sequence in that it contains an Alanine residue instead of a Threonine (i.e. LPKAG) (Table 1). It has been recently been published that S. aureus contains two sortase genes, srtA and srtB (Pallen, 2001). It is possible that this variant form of the LPXTG motif is processed by the second sortase gene, which is absent in L. lactis. This would also explain the slight increase in size of the KnkA protein observed in the protoplast fraction, as the cell wall sorting signal has not been cleaved.
  • KesK was detected in the cell wall fraction of L. lactis but migrated at a smaller molecular weight than the KesK protein released from the cell wall of S. aureus. The majority of MSCRAMMs expressed on the surface of L. lactis are prone to proteolysis during the cell wall extraction procedure (Louise O'Brien, personal communication). Therefore, it is possible that the KesK protein released from the surface of L. lactis represents a truncated form of KesK. Shorter digestion times with lysozyme and mutanolysin has been shown to limit the extent of proteolysis.
  • Expression of in Silico-Predicted MSCRAMMs In Vivo:
  • Convalescent-phase sera from 33 patients recovering from S. aureus infections were tested in their ability to recognize the purified N-terminal his-tag fusion proteins in an ELISA assay. Pooled sera from children and healthy blood donors were used as negative controls. A positive reaction was taken as a value equal to or greater than twice the value of the negative control. FIGS. 5A-5D illustrate that all of the proteins were recognized by 27-42% of the patients suggesting that these proteins are expressed in vivo and are immunogenic during infection of the host.
  • References:
    • Komatsuzawa, H., Ohta, K., Sugai, M., Fujiwara, T., Glanzmann, P., Berger-Bachi, B., Suginaka, H. (2000) Tn551-mediated insertional inactivation of the fmtB gene encoding a cell wall-associated protein abolishes methicillin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 45: 421-31.
    • Sinha, B., Francois, P., Que, Y. A., Hussain, M., Heilmann, C., Moreillon, P., Lew, D., Krause, K. H., Peters, G., Herrmann, M. (2000) Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells.
    • Infect. Immun. 68: 6871-6878.
    • Pallen, M. J., Lam, A. C., Antonio, M., Dunbar, K. (2000) An embarrassment of sortases—a richness of substrates? Trends. Microbiol. 9: 97-101
    Example 2 Isolation and Sequencing of Cross-Reactive Proteins from S. Aureus and from Coagulase-Negative Staphylococci
  • It has been recently shown that S. epidermidis contains surface proteins structurally related to S. aureus MSCRAMM® proteins (U.S. Ser. No. 09/386,962). One protein from S. aureus is of particular interest since it has a close homologue in S. epidermidis. The protein is called DsqA or SasA (S. aureus) and DgsK (S. epidermidis). They are characterized by a typical “A” domain of approximately 500 amino acid residues, followed by two B repeats of 88 residues that are ˜40% identical, and a unique SXSX dipeptide repeat that can vary in length depending on the strain. Contained within the A domain of the S. aureus DsqA/SasA is a 180 residue region that has ˜40% identity to a similar sized domain within region A of S. aureus proteins RrkN, Pls and S. epidermidis protein Aap The A regions of the DsqA/SasA and DgsK proteins are 46% identical at the amino acid level, the BB repeats are 50% identical. Active and passive immunization strategies that include; vaccines, polyclonal and monoclonal antibodies recognizing both S. aureus and coagulase-negative staphylococcal proteins are the subject of this invention.
    • Specific Examples of Antibodies that Cross-React with Coagulase-Negative Staphylococci and S. aureus.
  • Coagulase-negative staphylococcal DgsK A-Domain:
    Amino Acid Sequence
    ASETPITSEISSNSETVANQNSTTIKNSQKETVNSTSLESNHSNSTNKQMSSEVTN (SEQ ID NO:17)
    TAQSSEKAGISQQSSETSNQSSKLNTYASTDHVESTTINNDNTAQQDQNKSSNVT
    SKSTQSNTSSSEKNISSNLTQSIETKATDSLATSEARTSTNQISNLTSTSTSNQSSP
    TSFANLRTFSRFTVLNTMAAPTTTSTTTTSSLTSNSVVVNKDNFNEHMNLSGSATY
    DPKTGIATLTPDAYSQKGAISLNTRLDSNRSFRFIGKVNLGNRYEGYSPDGVAGGD
    GIGFAFSPGPLGQIGKEGAAVGIGGLNNAFGFKLDTYHNTSTPRSDAKAKADPRN
    VGGGGAFGAFVSTDRNGMATTEESTAAKLNVQPTDNSFQDFVIDYNGDTKVMTV
    TYAGQTFTRNLTDWIKNSGGTTFSLSMTASTGGAKNLQQVQFGTFEYTESAVAKV
    RYVDANTGKDIIPPKTIAGEVDGTVNIDKQLNNFKNLGYSYVGTDALKAPNYTETSG
    TPTLKLTNSSQTVIYKFKDVQ
    S. aureus SasA A-domain:
    Amino Acid Sequence
    ASDAPLTSELNTQSETVGNQNSTTIEASTSTADSTSVTKNSSSVQTSNSDTVSSEK (SEQ ID NO:18)
    SEKVTSTTNSTSNQQEKLTSTSESTSSKNTTSSSDTKSVASTSSTEQPINTSTNQS
    TASNNTSQSTTPSSVNLNKTSTTSTSTAPVKLRTFSRLAMSTFASAATTTAVANTI
    TVNKDNLKQYMTTSGNATYDQSTGIVTLTQDAYSQKGAITLGTRIDSNKSFHFSGK
    VNLGNKYEGHGNGGDGIGFAFSPGVLGETGLNGAAVGIGGLSNAFGFKLDTYHNT
    SKPNSAAKANADPSNVAGGGAFGAFVTTDSYGVATTYTSSSTADNAAKLNVQPT
    NNTFQDFDINYNGDTKVMTVKYAGQTWTRNISDWIAKSGTTNFSLSMTASTGGAT
    NLQQVQFGTFEYTESAVTQVRYVDVTTGKDIIPPKTYSGNVDQVVTIDNQQSALTA
    KGYNYTSVDSSYASTYNDTNKTVKMTNAGQSVTYYFTDVV
  • The entire sequence of the Aap protein and the DNA coding therefor (with an indication of the presence of the A domain) is shown below:
    S. epidermidis Aap Protein (A-domain underlined)
    MGKRRQGPINKKVDFLPNKLNKYSIRKFTVGTASILLGSTLIFGSSSHEAKAAEEKQ (SEQ ID NO:19)
    VDPITQANQNDSSERSLENTNQPTVNNEAPQMSSTLQAEEGSNAEAPQSEPTKA
    EEGGNAEAAQSEPTKAEEGGNAEAPQSEPTKAEEGGNAEAAQSEPTKTEEGSNV
    KAAQSEPTKAEEGSNAEAPQSEPTKTEEGSNAKAAQSEPTKAEEGGNAEAAQSE
    PTKTEEGSNAEAPQSEPTKAEEGGNAEAPQSEPTKTEEGGNAEAPNVPTIKANSD
    NDTQTQFSEAPTRNDLARKEDIPAVSKNEELQSSQPNTDSKIEPTTSEPVNLNYSS
    PFMSLLSMPADSSSNNTKNTIDIPPTTVKGRDNYDFYGRVDIESNPTDLNATNLTR
    YNYGQPPGTTTAGAVQFKNQVSFDKDFDFNIRVANNRQSNTTGADGWGFMFSK
    KDGDDFLKNGGILREKGTPSAAGFRIDTGYYNNDPLDKIQKQAGQGYRGYGTFVK
    NDSQGNTSKVGSGTPSTDFLNYADNTTNDLDGKFHGQKLNNVNLKYNASNQTFT
    ATYAGKTWTATLSELGLSPTDSYNFLVTSSQYGNGNSGTYASGVMRADLDGATL
    TYTPKAVDGDPIISTKEIPFNKKREFDPNLAPGTEKVVQKGEPGIETTTTPTYVNPN
    TGEKVGEGEPTEKITKQPVDEIVHYGGEEIKPGHKDEFDPNAPKGSQTTQPGKPG
    VKNPDTGEVVTPPVDDVTKYGPVDGDPITSTEEIPFDKKREFNPDLKPGEERVKQ
    KGEPGTKTITTPTTKNPLTGEKVGEGEPTEKITKQPVDEITEYGGEEIKPGHKDEFD
    PNAPKGSQEDVPGKPGVKNPGTGEVVTPPVDDVTKYGPVDGDPITSTEEIPFDKK
    REFNPDLKPGEERVKQKGEPGTKTITTPTTKNPLTGEKVGEGEPTEKITKQPVDEI
    VHYGGEQIPQGHKDEFDPNAPVDSKTEVPGKPGVKNPDTGEVVTPPVDDVTKYG
    PVDGDSITSTEEIPFDKKREFDPNLAPGTEKVVQKGEPGTKTITTPTTKNPLTGEKV
    GEGKSTEKVTKQPVDEIVEYGPTKAEPGKPAEPGKPAEPGKPAEPGTPAEPGKPA
    EPGTPAEPGKPAEPGKPAEPGKPAEPGKPAEPGTPAEPGTPAEPGKPAEPGTPA
    EPGKPAEPGTPAEPGKPAESGKPVEPGTPAQSGAPEQPNRSMHSTDNKNQLPD
    TGENRQANEGTLVGSLLAIVGSLFIFGRRKKGNEK
    S. epidermidis aap DNA
    atgggcaaac gtagacaagg tcctattaat aaaaaagtgg (SEQ ID NO:20)
    attttttacc taacaaatta aacaagtatt ctataagaaa attcactgtt ggtacggcct
    caatattact tggttcgaca cttatttttg gaagtagtag ccatgaagcg aaagctgcag
    aagaaaaaca agttgatcca attacacaag ctaatcaaaa tgatagtagt gaaagatcac
    ttgaaaacac aaatcaacct actgtaaaca atgaagcacc acagatgtct tctacattgc
    aagcagaaga aggaagcaat gcagaagcac ctcaatctga gccaacgaag gcagaagaag
    gaggcaatgc agaagcagct caatctgagc caacgaaggc agaagaagga ggcaatgcag
    aagcacctca atctgagcca acgaaggcag aagaaggagg caatgcagaa gcagctcaat
    ctgagccaac gaagacagaa gaaggaagca acgtaaaagc agctcaatct gagccaacga
    aggcagaaga aggaagcaat gcagaagcac ctcaatctga gccaacgaag acagaagaag
    gaagcaacgc aaaagcagct caatctgagc caacgaaggc agaagaagga ggcaatgcag
    aagcagctca atctgagcca acgaagacag aagaaggaag caatgcagaa gcacctcaat
    ctgagccaac gaaggcagaa gaaggaggca atgcagaagc acctcaatct gagccaacga
    agacagaaga aggaggcaat gcagaagcac cgaatgttcc aactatcaaa gctaattcag
    ataatgatac acaaacacaa ttttcagaag cccctacaag aaatgaccta gctagaaaag
    aagatatccc tgctgtttct aaaaacgagg aattacaatc atcacaacca aacactgaca
    gtaaaataga acctacaact tcagaacctg tgaatttaaa ttatagttct ccgtttatgt
    ccttattaag catgcctgct gatagttcat ccaataacac taaaaataca atagatatac
    cgccaactac ggttaaaggt agagataatt acgattttta cggtagagta gatatcgaaa
    gtaatcctac agatttaaat gcgacaaatt taacgagata taattatgga cagccacctg
    gtacaacaac agctggtgca gttcaattta aaaatcaagt tagttttgat aaagatttcg
    actttaacat tagagtagca aacaatcgtc aaagtaatac aactggtgca gatggttggg
    gctttatgtt cagcaagaaa gatggggatg atttcctaaa aaacggtggt atcttacgtg
    aaaaaggtac acctagtgca gctggtttca gaattgatac aggatattat aataacgatc
    cattagataa aatacagaaa caagctggtc aaggctatag agggtatggg acatttgtta
    aaaatgactc ccaaggtaat acttctaaag taggatcagg tactccatca acagattttc
    ttaactacgc agataatact actaatgatt tagatggtaa attccatggt caaaaattaa
    ataatgttaa tttgaaatat aatgcttcaa atcaaacttt tacagctact tatgctggta
    aaacttggac ggctacgtta tctgaattag gattgagtcc aactgatagt tacaattttt
    tagttacatc aagtcaatat ggaaatggta atagtggtac atacgcaagt ggcgttatga
    gagctgattt agatggtgca acattgacat acactcctaa agcagtcgat ggagatccaa
    ttatatcaac taaggaaata ccatttaata agaaacgtga atttgatcca aacttagccc
    caggtacaga aaaagtagtc caaaaaggtg aaccaggaat tgaaacaaca acaacaccaa
    cttatgtcaa tcctaataca ggagaaaaag ttggcgaagg tgaaccaaca gaaaaaataa
    caaaacaacc agtggatgaa atcgttcatt atggtggcga agaaatcaag ccaggccata
    aggatgaatt tgatccaaat gcaccgaaag gtagtcaaac aacgcaacca ggtaagccgg
    gggttaaaaa tcctgataca ggcgaagtag ttactccacc tgtggatgat gtgacaaaat
    atggtccagt tgatggagat ccgatcacgt caacggaaga aattccattc gacaagaaac
    gtgaattcaa tcctgattta aaaccaggtg aagagcgtgt taaacaaaaa ggtgaaccag
    gaacaaaaac aattacaaca ccaacaacta agaacccatt aacaggggaa aaagttggcg
    aaggtgaacc aacagaaaaa ataacaaaac aaccagtaga tgaaatcaca gaatatggtg
    gcgaagaaat caagccaggc cataaggatg aatttgatcc aaatgcaccg aaaggtagcc
    aagaggacgt tccaggtaaa ccaggagtta aaaaccctgg aacaggcgaa gtagtcacac
    caccagtgga tgatgtgaca aaatatggtc cagttgatgg agatccgatc acgtcaacgg
    aagaaattcc attcgacaag aaacgtgaat tcaatcctga tttaaaacca ggtgaagagc
    gcgttaaaca gaaaggtgaa ccaggaacaa aaacaattac aacgccaaca actaagaacc
    cattaacagg agaaaaagtt ggcgaaggtg aaccaacaga aaaaataaca aaacaaccag
    tggatgagat tgttcattat ggtggtgaac aaataccaca aggtcataaa gatgaatttg
    atccaaatgc acctgtagat agtaaaactg aagttccagg taaaccagga gttaaaaatc
    ctgatacagg tgaagttgtt accccaccag tggatgatgt gacaaaatat ggtccagttg
    atggagattc gattacgtca acggaagaaa ttccgtttga taaaaaacgc gaatttgatc
    caaacttagc gccaggtaca gagaaagtcg ttcaaaaagg tgaaccagga acaaaaacaa
    ttacaacgcc aacaactaag aacccattaa caggagaaaa agttggcgaa ggtaaatcaa
    cagaaaaagt cactaaacaa cctgttgacg aaattgttga gtatggtcca acaaaagcag
    aaccaggtaa accagcggaa ccaggtaaac cagcggaacc aggtaaacca gcggaaccag
    gtacgccagc agaaccaggt aaaccagcgg aaccaggtac gccagcagaa ccaggtaaac
    cagcggaacc aggtaaacca gcggaaccag gtaaaccagc ggaaccaggt aaaccagcgg
    aaccaggtac gccagcagaa ccaggtacgc cagcagaacc aggtaaacca gcggaaccag
    gtacgccagc agaaccaggt aaaccagcgg aaccaggtac gccagcagaa ccaggtaaac
    cagcggaatc aggtaaacca gtggaaccag gtacgccagc acaatcaggt gcaccagaac
    aaccaaatag atcaatgcat tcaacagata ataaaaatca attacctgat acaggtgaaa
    atcgtcaagc taatgaggga actttagtcg gatctctatt agcaattgtc ggatcattgt
    tcatatttgg tcgtcgtaaa aaaggtaatg aaaaataatt tcatataaaa actttctgcc
    attaa
    A-Domain from S. epidermidis Aap (amino acids 55-600)
    55EKQVDPITQANQNDSSERSLENTNQPTVNNEAPQMSSTLQAEEGSNAEAPQSE (SEQ ID NO:21)
    PTKAEEGGNAEAAQSEPTKAEEGGNAEAPQSEPTKAEEGGNAEAAQSEPTKTEE
    GSNVKAAQSEPTKAEEGSNAEAPQSEPTKTEEGSNAKAAQSEPTKAEEGGNAEA
    AQSEPTKTEEGSNAEAPQSEPTKAEEGGNAEAPQSEPTKTEEGGNAEAPNVPTIK
    ANSDNDTQTQFSEAPTRNDLARKEDIPAVSKNEELQSSQPNTDSKIETTSEPVNL
    NYSSPFMSLLSMPADSSSNNTKNTIDIPPTTVKGRDNYDFYGRVDIESNPTDLNAT
    NLTRYNYGQPPGTTTAGAVQFKNQVSFDKDFDFNIRVANNRQSNTTGADGWGF
    MFSKKDGDDFLKNGGILREKGTPSAAGFRIDTGYYNNDPLDKIQKQAGQGYRGYG
    TFVKNDSQGNTSKVGSGTPSTDFLNYADNTTNDLDGKFHGQKLNNVNLKYNASN
    QTFTATYAGKTWTATLSELGLSPTDSYNFLVTSSQYGNGNSGTYASGVMRADLD
    GA600

    Protein Production and Purification
  • Using PCR, the A domain of DgsK or SasA was amplified from the sequences described above and subcloned into the E. coli expression vector PQE-30 (Qiagen), which allows for the expression of a recombinant fusion protein containing six histidine residues. This vector was subsequently transformed into the E. coli strain ATCC 55151, grown in a 15-liter fermentor to an optical density (OD600) of 0.7 and induced with 0.2 mM isopropyl-1-beta-D galactoside (IPTG) for 4 hours. The cells were harvested using an AG Technologies hollow-fiber assembly (pore size of 0.45 Om) and the cell paste frozen at −80° C. Cells were lysed in 1×PBS (10 mL of buffer/1 g of cell paste) using 2 passes through the French Press @ 1100psi. Lysed cells were spun down at 17,000 rpm for 30 minutes to remove cell debris. Supernatant was passed over a 5-mL HiTrap Chelating (Pharmacia) column charged with 0.1M NiCl2. After loading, the column was washed with 5 column volumes of 10 mM Tris, pH 8.0, 100 mM NaCl (Buffer A). Protein was eluted using a 0-100% gradient of 10 mM Tris, pH 8.0, 100 mM NaCl, 200 mM imidazole (Buffer B) over 30 column volumes. SdrGN1N2N3 or SdrGN2N3 eluted at ˜13% Buffer B (26 mM imidazole). Absorbance at 280 nm was monitored. Fractions containing SdrGN1N2N3 or SdrGN2N3 were dialyzed in 1×PBS.
  • Each protein was then put through an endotoxin removal protocol. Buffers used during this protocol were made endotoxin free by passing over a 5-mL Mono-Q sepharose (Pharmacia) column. Protein was divided evenly between 4×15 mL tubes. The volume of each tube was brought to 9 mL with Buffer A. 1 mL of 10% Triton X-114 was added to each tube and incubated with rotation for 1 hour at 4° C. Tubes were placed in a 37° C. water bath to separate phases. Tubes were spun down at 2,000 rpm for 10 minutes and the upper aqueous phase from each tube was collected and the detergent extraction repeated. Aqueous phases from the 2nd extraction were combined and passed over a 5-mL IDA chelating (Sigma) column, charged with 0.1M NiCl2 to remove remaining detergent. The column was washed with 9 column volumes of Buffer A before the protein was eluted with 3 column volumes of Buffer B. The eluant was passed over a 5-mL Detoxigel (Sigma) column and the flow-through collected and reapplied to the column. The flow-through from the second pass was collected and dialyzed in 1×PBS. The purified product was analyzed for concentration, purity and endotoxin level before administration into the mice.
  • Monoclonal Antibody Production
  • E. coli expressed and purified recombinant SasA and DsgK proteins were used to generate a panel of murine monoclonal antibodies while the mouse sera was used as a source of polyclonal antibodies. Briefly, a group of Balb/C or SJL mice received a series of subcutaneous immunizations of 1-10 mg of protein in solution or mixed with adjuvant as described in the Table below.
  • Immunization Schemes
    Day Amount (μg) Route Adjuvant
    RIMMS
    Injection
    #
    1 0 5 Subcutaneous FCA/RIBI
    #
    2 2 1 Subcutaneous FCA/RIBI
    #
    3 4 1 Subcutaneous FCA/RIBI
    #
    4 7 1 Subcutaneous FCA/RIBI
    #
    5 9 1 Subcutaneous FCA/RIBI
    Conventional
    Injection
    Primary
    0 5 Subcutaneous FCA
    Boost #
    1 14 1 Intraperitoneal RIBI
    Boost #
    2 28 1 Intraperitoneal RIBI
    Boost #
    3 42 1 Intraperitoneal RIBI
  • At the time of sacrifice (RIMMS) or seven days after a boost (conventional) serum was collected and titered in ELISA assays against MSCRAMM® proteins or on whole cells (S. epidermidis and S. aureus). Three days after the final boost, the spleens or lymph nodes were removed, teased into a single cell suspension and the lymphocytes harvested. The lymphocytes were then fused to a P3X63Ag8.653 myeloma cell line (ATCC #CRL-1580). Cell fusion, subsequent plating and feeding were performed according to the Production of Monoclonal Antibodies protocol from Current Protocols in Immunology (Chapter 2, Unit 2.).
  • Any clones that were generated from the fusion were then screened for specific anti-SasA antibody production using a standard ELISA assay. Positive clones were expanded and tested further for activity in a whole bacterial cell binding assay by flow cytometry and SasA binding by Biacore analysis.
  • Biacore Analysis
  • Throughout the analysis, the flow rate remained constant at 10 ml/min. Prior to the SasA or DgsK injection, test antibody was adsorbed to the chip via RAM-Fc binding. At time 0, SasA or DgsK at a concentration of 30 mg/ml was injected over the chip for 3 min followed by 2 minutes of dissociation. This phase of the analysis measured the relative association and disassociation kinetics of the Mab/SasA or DgsK interaction.
  • Binding to Whole Bacteria
  • Bacterial samples S. aureus Newman, S. aureus 67-0, S. aureus 397 (Sal6), S. aureus Wood, S. aureus 8325-4, methicillin resistant S. aureus MRSA 16, S. epidermidis ATCC 35984, S. epidermidis HB, S. epidermidis CN-899 and S. haemolyticus ATCC 43253 were collected, washed and incubated with Mab or PBS alone (control) at a concentration of 2 μg/ml after blocking with rabbit IgG (50 mg/ml). Following incubation with antibody, bacterial cells were incubated with Goat-F(ab′)2-Anti-Mouse-F(ab′)2-FITC which served as the detection antibody. After antibody labeling, bacterial cells were aspirated through the FACScaliber flow cytometer to analyze fluorescence emission (excitation: 488, emission: 570). For each bacterial strain, 10,000 events were collected and measured. These data indicate that antibodies against S. aureus SasA were able to recognize a homologous protein on the surface of coagulase-negative staphylococci. The data support Western blot analysis demonstrating that rabbit polyclonal antibodies against S. aureus SasA cross-react with a protein released from the cell surface of S. epidermidis HB as well as the recombinant A-region from DsgK cloned from S. epidermidis (see Table below and FIG. 6);
    Polyclonal Sera Reactivity
    397
    (SAL Wood MRSA ATCC CN- ATCC
    Newman 67-0 6) 46 8325-4 16 35984 HB 899 43253
    Normal − − − − − − − − − −
    Mouse
    Sera
    Mouse + + +/− − + + + + + +
    anti-
    SasA

Claims (21)

1. An isolated antibody which is capable of binding to a staphylococcal surface protein selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 17, 19 and 21.
2. The antibody according to claim 1 wherein the antibody is raised against the A domain of the surface protein.
3. The antibody according to claim 1, wherein the antibody is suitable for parenteral, oral, intranasal, subcutaneous, aerosolized or intravenous administration in a human or animal.
4. The antibody according to claim 1, wherein said antibody is a polyclonal antibody.
5. The antibody according to claim 1, wherein said antibody is a monoclonal antibody.
6. The antibody according to claim 5 wherein the monoclonal antibody is of a type selected from the group consisting of murine, chimeric, humanized and human monoclonal antibodies.
7. The antibody according to claim 5 wherein the antibody is a single chain monoclonal antibody.
8. The antibody according to claim 1 which comprises an antibody fragment having the same binding specificity of an antibody which is capable of biding to a staphylococcal surface protein having the sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 17, 19 and 21.
9. The antibody according to claim 1 that is raised against a protein having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 17, 19 and 21.
10. The antibody according to claim 1 wherein the surface protein has an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of nucleic acid sequences SEQ ID NOS. 1, 3, 5, 7, 9, 11, 13, 15, 20 and the nucleic acid sequences coding for the A domain of the Aap protein or degenerates thereof.
11. Isolated antisera containing an antibody according to claim 1.
12. A diagnostic kit comprising an antibody according to claim 1 and means for detecting binding by that antibody.
13. A diagnostic kit according to claim 12 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.
14. A method of diagnosing an infection of S. aureus comprising adding an antibody according to claim 1 to a sample suspected of being infected with S. aureus, and determining if antibodies have bound to the sample.
15. A pharmaceutical composition for treating or preventing an infection of S. aureus comprising an effective amount of the antibody of claim 1 and a pharmaceutically acceptable vehicle, carrier or excipient.
16. A method of treating or preventing an infection of S. aureus comprising administering to a human or animal patient an effective amount of an antibody according to claim 1.
17. A method of inducing an immunological response comprising administering to a human or animal an immunogenic amount of an isolated protein selected from the group consisting of the amino acid sequences SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 17, 18, 19 and 21.
18. An isolated antibody according to claim 1 that has the ability to bind to an amino acid sequence coded by the nucleic acid sequence of SEQ ID NOS. 1, 3, 5, 7, 9, 11, 13, 15, 20 and the nucleic acid sequences coding for the A domain of the Aap protein or degenerates thereof.
19. An isolated active fragment from the A domain of the DsqA protein.
20. A composition comprising the isolated antibody according to claim 1 and a physiologically acceptable antibiotic.
21. A vaccine for treating or preventing an infection of S. aureus comprising an amount of a protein sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 17, 18, 19 and 21 in an amount effective to elicit an immune response, and a pharmaceutically acceptable vehicle, carrier or excipient.
US11/020,509 2001-06-15 2004-12-27 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus Abandoned US20050106648A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/020,509 US20050106648A1 (en) 2001-06-15 2004-12-27 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
US12/365,481 US7968100B2 (en) 2001-06-15 2009-02-04 Surface proteins from coagulase-negative staphylococci and Staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29809801P 2001-06-15 2001-06-15
US10/172,502 US6841154B2 (en) 2001-06-15 2002-06-17 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
US11/020,509 US20050106648A1 (en) 2001-06-15 2004-12-27 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/172,502 Division US6841154B2 (en) 2001-06-15 2002-06-17 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/365,481 Division US7968100B2 (en) 2001-06-15 2009-02-04 Surface proteins from coagulase-negative staphylococci and Staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies

Publications (1)

Publication Number Publication Date
US20050106648A1 true US20050106648A1 (en) 2005-05-19

Family

ID=23149018

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/172,502 Expired - Lifetime US6841154B2 (en) 2001-06-15 2002-06-17 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
US11/020,509 Abandoned US20050106648A1 (en) 2001-06-15 2004-12-27 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
US12/365,481 Expired - Fee Related US7968100B2 (en) 2001-06-15 2009-02-04 Surface proteins from coagulase-negative staphylococci and Staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/172,502 Expired - Lifetime US6841154B2 (en) 2001-06-15 2002-06-17 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/365,481 Expired - Fee Related US7968100B2 (en) 2001-06-15 2009-02-04 Surface proteins from coagulase-negative staphylococci and Staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies

Country Status (9)

Country Link
US (3) US6841154B2 (en)
EP (3) EP2339344A1 (en)
JP (2) JP4424984B2 (en)
CN (1) CN100359327C (en)
AU (2) AU2002322127B2 (en)
CA (1) CA2450939C (en)
HK (1) HK1068949A1 (en)
MX (1) MXPA03011701A (en)
WO (1) WO2002102829A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US20110027265A1 (en) * 2007-08-31 2011-02-03 The University Of Chicago Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions
US20110206676A1 (en) * 2008-07-29 2011-08-25 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US9315554B2 (en) 2010-07-02 2016-04-19 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9567379B2 (en) 2009-04-03 2017-02-14 The University Of Chicago Compositions and methods related to protein A (SpA) variants

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (en) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2808598A1 (en) * 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
EP1545617A1 (en) * 2002-10-03 2005-06-29 Intercell AG Use of molecules which interact with the haptoglobin receptor ligand binding
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
SI1651166T1 (en) * 2003-07-24 2010-06-30 Merck Sharp & Dohme Polypeptides for inducing a protective immune response against staphylococcus aureus
AU2005214061B2 (en) * 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20070172498A1 (en) * 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
EP1791560A4 (en) * 2004-09-17 2009-01-14 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1804833A2 (en) 2004-09-22 2007-07-11 GlaxoSmithKline Biologicals SA Staphylococcal immunogenic compositions
KR20070085457A (en) * 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 Vaccines, compositions and methods based on staphylococcus aureus iron-regulated surface determinants isda, isdb, and isdc
AU2006214534B2 (en) 2005-02-14 2012-07-19 Epitopix, Llc Polypeptides from Staphylococcus aureus and methods of use
US8475798B2 (en) * 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
EP2368570A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP1996231A4 (en) * 2006-02-22 2010-09-15 Texas A & M Univ Sys Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
WO2009005536A2 (en) * 2006-11-22 2009-01-08 3M Innovative Properties Company Methods of capturing bacterial whole cells and methods of analyzing samples for bacteria
US20100047252A1 (en) * 2006-11-22 2010-02-25 3M Innovative Properties Company Antibody with protein a selectivity
US7488807B2 (en) * 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
CA2716706C (en) 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
JP2012521441A (en) 2009-03-23 2012-09-13 エピトピックス，リミティド ライアビリティ カンパニー Immunization compositions containing polypeptides and gram positive polypeptides and methods of use thereof
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
SI2445522T1 (en) 2009-06-22 2017-10-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
BR112012004806B8 (en) 2009-09-02 2022-10-04 Novartis Ag immunogenic compositions that include modulators of tlr activity, method to increase the effectiveness of said composition and use
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
JP5848748B2 (en) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ Compounds (cysteine-based lipopeptides) and compositions as TLR2 agonists for use in the treatment of infectious diseases, inflammation, respiratory diseases, etc.
CN102268444B (en) * 2010-06-03 2015-05-13 中国人民解放军军事医学科学院生物工程研究所 Expression of truncated SasA protein of staphylococcus aureus in escherichia coli and application thereof
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CA2819120C (en) 2010-12-22 2016-07-05 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens
CN102649817A (en) * 2011-02-24 2012-08-29 复旦大学 Monoclonal antibody for inhibiting formation of bacterial biofilm
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN104098693B (en) * 2014-07-15 2017-05-17 中国人民解放军军事医学科学院生物工程研究所 Monoclonal antibody resistant to SasA (staphylococcus aureus surface protein A) antigen and application of monoclonal antibody
WO2016095832A1 (en) * 2014-12-18 2016-06-23 The University Of Hong Kong Immunotherapeutic targets against staphylococcus aureus
US11446371B2 (en) 2015-11-05 2022-09-20 The Texas A&M University System Targeting of ligand binding sites in ClfA
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
MX2020008417A (en) 2018-02-12 2020-11-11 Inimmune Corp Toll-like receptor ligands.
WO2022096590A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Phage-derived particles for in situ delivery of dna payload into c. acnes population

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US519596A (en) 1894-05-08 Tian voigt
JPS4954801A (en) 1972-09-27 1974-05-28
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
US5571514A (en) 1987-06-01 1996-11-05 Alfa Laval Ab Fibronectin binding protein as well as its preparation
SE8801894D0 (en) 1988-05-20 1988-05-20 Alfa Laval Agri Int FIBRONECT BINING PROTEIN
US5789549A (en) 1988-05-20 1998-08-04 Alfa Laval Agri International Aktiebolag Fibronectin binding protein
SE8901687D0 (en) * 1989-05-11 1989-05-11 Alfa Laval Agri Int FIBRONECTIN BINDING PROTEIN AS WELL AS IT'S PREPARATION
US5440014A (en) 1990-08-10 1995-08-08 H+E,Uml/Oo/ K; Magnus Fibronectin binding peptide
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
CA2155413A1 (en) * 1993-02-05 1994-08-18 Martin Karl Russel Burnham Fibronectin binding protein; monoclonal antibody and their use in preventing bacterial adhesion
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5707702A (en) 1994-12-14 1998-01-13 Brady, Jr.; Robert F. Epoxy pipelining composition and method of manufacture
US6013482A (en) * 1996-10-15 2000-01-11 Smithkline Beecham Plc Cell surface protein compounds
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
JP2001505061A (en) * 1996-02-29 2001-04-17 ワシントン ユニヴァーシティ Bacterial elastin binding protein, nucleic acid sequence encoding the same, and diagnostic and therapeutic methods using the same
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
SE9602496D0 (en) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
CA2310217A1 (en) * 1997-11-26 1999-06-03 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
CA2341177A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
WO2000012689A1 (en) * 1998-08-31 2000-03-09 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
WO2000071585A1 (en) 1999-05-03 2000-11-30 Medarex, Inc. Human antibodies to staphylococcus aureus
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (en) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US20110027265A1 (en) * 2007-08-31 2011-02-03 The University Of Chicago Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions
US11639379B2 (en) 2007-08-31 2023-05-02 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US8840906B2 (en) 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US20110206676A1 (en) * 2008-07-29 2011-08-25 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US9567379B2 (en) 2009-04-03 2017-02-14 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9315554B2 (en) 2010-07-02 2016-04-19 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US10464971B2 (en) 2010-07-02 2019-11-05 The University Of Chicago Compositions and methods related to Protein A (SpA) Variants
US11059866B2 (en) 2010-07-02 2021-07-13 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US11939358B2 (en) 2010-07-02 2024-03-26 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides

Also Published As

Publication number Publication date
EP2339344A1 (en) 2011-06-29
JP2010047581A (en) 2010-03-04
EP1423701A4 (en) 2006-03-29
MXPA03011701A (en) 2004-12-06
CA2450939A1 (en) 2002-12-27
EP1423701A2 (en) 2004-06-02
WO2002102829A2 (en) 2002-12-27
US20090202578A1 (en) 2009-08-13
US6841154B2 (en) 2005-01-11
JP4424984B2 (en) 2010-03-03
HK1068949A1 (en) 2005-05-06
WO2002102829A3 (en) 2004-03-25
AU2008249159A1 (en) 2008-12-11
AU2008249159B2 (en) 2011-04-14
CA2450939C (en) 2012-11-06
EP2320233A1 (en) 2011-05-11
AU2002322127B2 (en) 2008-08-21
CN1543569A (en) 2004-11-03
JP2004534080A (en) 2004-11-11
US7968100B2 (en) 2011-06-28
EP1423701B1 (en) 2012-07-25
CN100359327C (en) 2008-01-02
US20030185833A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
US7968100B2 (en) Surface proteins from coagulase-negative staphylococci and Staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies
AU2002322127A1 (en) Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
US7364738B2 (en) Monoclonal antibodies to the CLFA protein and method of use in treating infections
US8124107B2 (en) Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
AU2002256985A1 (en) Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
US8475798B2 (en) Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2003076470A1 (en) Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
EP1334131B1 (en) Monoclonal antibodies to the map protein and method of use in treating or preventing infections
WO2008089476A1 (en) Monoclonal antibodies recognizing the enterococcus faecium acm protein

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION